Cancer Research and Treatment

Original Articles

Comparative Clinical and Economic Analysis of Robotic versus Video-Assisted Thoracoscopic Anatomical Resection for Lung Cancer: Ji Hyeon Park, Young Eun Hong, Hana Shim, Taeyoung Yun, Bubse Na, Kwon Joong Na, Hyun Joo Lee, In Kyu Park, Young Tae Kim, Chang Hyun Kang; Received February 27, 2025 Accepted March 16, 2026 Published online March 17, 2026; DOI: https://doi.org/10.4143/crt.2025.230 [Epub ahead of print]

Abstract PDF: Purpose
This study aimed to compare the clinical outcomes and costs of robotic-assisted thoracic surgery (RATS) and video-assisted thoracic surgery (VATS) in patients undergoing minimally invasive anatomical resection for primary lung cancer.
Materials and Methods
A retrospective analysis was conducted on 2,086 patients who underwent surgery at a single institution from January 2017 to July 2020, including 134 RATS and 1,952 VATS cases. Propensity score matching (PSM) was applied, resulting in 268 matched patients (134 RATS and 134 VATS). Cost data were obtained from hospital billing files, encompassing 20 categories, including total hospitalization fees, anesthesia fees, surgery fees, costs of surgical instruments and materials, and general examination fees.
Results
After PSM, RATS patients had a shorter median postoperative stay (5 days vs. 6 days, p=0.009) and lower thoracotomy conversion rate (1.5% vs. 14.9%, p < 0.001) than VATS. However, RATS incurred higher total costs by an average of $1,228 (p < 0.001), mainly due to increased surgical expenses ($1,163, p < 0.001). In multivariate analysis, RATS (12.41%, p < 0.001), neoadjuvant therapy (13.3%, p=0.005), complications (4.2%, p < 0.001), and length of stay (2.0%, p < 0.001) were found to be associated with higher costs.
Conclusion
Although RATS has been shown to reduce the thoracotomy conversion rate and length of hospital stay, it incurs higher costs than VATS, primarily due to increased surgical expenses. The justification for RATS should be further evaluated through sustainability and cost-effectiveness studies with long-term follow-up.

749 View
64 Download

Safety and Efficacy of Combining Metastasis-Directed Stereotactic Ablative Radiation Therapy with Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors in Metastatic Hepatocellular Carcinoma: Eunyeong Yang, Jeong Il Yu, Hee Chul Park, Myung Ji Goh, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Moon Seok Choi, Jung Yong Hong, Minsuk Kwon, Nalee Kim; Received September 5, 2025 Accepted February 1, 2026 Published online February 3, 2026; DOI: https://doi.org/10.4143/crt.2025.966 [Epub ahead of print]

Abstract PDF Supplementary Material: Purpose
Immune checkpoint inhibitors (ICIs) have become a standard therapy for metastatic hepatocellular carcinoma (HCC), often as an alternative to tyrosine kinase inhibitors (TKIs). However, safety data combining ICIs with stereotactic ablative radiotherapy (SABR) remain limited. We compared the safety and efficacy of SABR combined with ICIs versus TKIs in patients with extrahepatic metastatic HCC.
Materials and Methods
This single-center retrospective study included patients with HCC who received SABR for extrahepatic metastases combined with either TKIs or ICIs within 30 days of SABR between January 2010 and June 2024. Adverse events (AEs; Common Terminology Criteria for Adverse Events ver. 5.0) and oncologic outcomes were evaluated using logistic regression and Cox models.
Results
Among 103 patients with 128 SABR-treated lesions, 72 patients (90 lesions) received SABR+TKI and 31 patients (38 lesions) received SABR+ICI. Acute AEs occurred only in the SABR+TKI group (8.9%), predominantly grade 1. Grade 3 late AEs were rare, occurring in one case in each group, while late AEs of lower grades were more frequent with SABR+ICI (any-grade: 57.9% vs. 25.6%, p < 0.001; grade ≥ 2: 23.7% vs. 8.9%, p=0.024). Multivariable analysis showed borderline increased risk of grade ≥ 2 late AEs with SABR+ICI (p=0.052). One-year local control, progression-free survival, and overall survival were 76.6%, 35.3%, and 72.3% respectively, with no significant differences between groups.
Conclusion
Metastasis-directed SABR combined with either TKIs or ICIs was generally well tolerated in patients with extrahepatic metastatic HCC, with rare grade 3 late AEs; grade ≥ 2 late AEs were more frequent with SABR plus ICIs, warranting prospective evaluation.

966 View
61 Download

Response to Neoadjuvant Systemic Therapy May Serve as an Indicator for Omitting Post–Breast-Conserving Surgery Radiation Therapy in Women with Early-Stage Breast Cancer: Chaofan Li, Yusheng Wang, Mengjie Liu, Shiyu Sun, Yiwei Jia, Jingkun Qu, Shuqun Zhang, Chong Du; Received June 1, 2025 Accepted September 7, 2025 Published online September 10, 2025; DOI: https://doi.org/10.4143/crt.2025.584 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
To avoid unnecessary toxicities and optimize the allocation of healthcare resources, it is crucial to adequately select patients with extremely low recurrence risk to downgrade or eliminate radiation therapy (RT).
Materials and Methods
From the Surveillance, Epidemiology, and End Results database, clinical data of 7,291 female patients with early-stage breast cancer who underwent neoadjuvant systemic therapy (NST) and breast-conserving surgery (BCS) were collected for this study. The patients were stratified by their response to NST, and the long-term survival, and risk of recurrence were assessed using Cox regression analysis and Fine-Gray competing risk models for those with and without post-BCS RT, respectively.
Results
Our results showed that female patients with early-stage breast cancer who achieved complete response (CR) to NST, omitting post-BCS RT achieved the same overall survival and disease-free survival as those who received the post-BCS RT, and the omission did not increase the risk of recurrence or breast cancer–specific death. For patients who did not achieve CR to NST, five clinical indicators (including age, N category, grade, response to NST, and molecular subtype) were employed to construct a nomogram for clinical prediction of overall survival, thereby identification of patients at relatively low recurrence risk. The validated results affirmed our model’s ability to accurately discriminate high- and low-risk patients and its promising clinical application value.
Conclusion
Post-BCS RT can be omitted for women with early-stage breast cancer who achieved CR to NST. For those who failed to achieve CR to NST, a nomogram was constructed for clinicians to decide whether to omit post-BCS RT or not based on individualized assessment.

2,021 View
90 Download

Lung and Thoracic cancer

Trends and Outcomes of Lung Cancer Surgery in South Korea: Joon Beom Park, Su-Jin Cho, Myung-Il Hahm, Danbee Kang, Seong Yong Park; Cancer Res Treat. 2026;58(2):443-453. Published online May 27, 2025; DOI: https://doi.org/10.4143/crt.2025.295

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study analyzed nationwide trends in lung cancer surgery in South Korea over 14 years, focusing on surgical volume, patient demographics, surgical approaches, and outcomes.
Materials and Methods
We performed a retrospective cohort study using nationwide health insurance claims data (124,334 cases) and robotic surgery data (1,740 cases) provided by the manufacturer. Patients who underwent lung cancer surgery between 2010 and 2023 were included. Annual trends were assessed using the annual percentage change (APC), and logistic as well as linear regression models were used to identify predictors of mortality and prolonged hospital stay.
Results
The annual surgical volume increased from 4,557 in 2010 to 14,184 in 2023 (APC, 8.86%; p < 0.001). Video-assisted thoracoscopic surgery (VATS) became the predominant approach, rising from 52.9% to 94.8% (APC, 4.11%; p < 0.001). Sub-lobar resections increased, with wedge resections growing from 9.0% to 18.5% (APC, 5.72%; p < 0.001) and segmentectomies from 3.0% to 17.9% (APC, 14.63%; p < 0.001). The proportion of female patients increased from 32.0% to 44.7% (APC, 2.39%; p < 0.001), while patients aged 70-79 years increased from 26.3% to 32.3% (APC, 1.60%; p < 0.001) and those aged ≥ 80 years from 2.0% to 6.2% (APC, 9.63%; p < 0.001). The median hospital stay decreased from 13 to 7 days (APC, –4.34%; p < 0.001), and 30-day mortality declined from 2.45% to 0.76% (APC, –8.32%; p < 0.001).
Conclusion
Lung cancer surgery in Korea has increased substantially, with a notable shift toward minimally invasive and lung-sparing techniques that have improved outcomes. However, persistent disparities underscore the need for a national surgical registry.

3,915 View
163 Download
2 Web of Science

Gastrointestinal cancer

Combined Transarterial Chemoembolization and External Beam Radiotherapy for Identifying Surgical Candidates for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Propensity Score–Weighted Analysis: Sumin Lee, Jinhong Jung, Jonggi Choi, So Yeon Kim, Jin Hyoung Kim, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Gi-Won Song, Jin-hong Park, Sang Min Yoon; Cancer Res Treat. 2026;58(1):275-283. Published online May 22, 2025; DOI: https://doi.org/10.4143/crt.2025.076

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to evaluate the role of hepatic resection in patients with objective responses after combined transarterial chemoembolization (TACE) and radiotherapy (RT) for hepatocellular carcinoma (HCC) with macroscopic vascular invasion (MVI).
Materials and Methods
We retrospectively reviewed the patients treated with combined TACE and RT for HCC with MVI between 2010 and 2015. Some of the patients with objective responses underwent hepatic resection or liver transplantation; to investigate the impact of surgery, patients with objective responses who did not undergo surgery were selected as the control group. Survival outcomes were compared using a propensity score–based stabilized inverse probability of treatment weighting method.
Results
Out of the 170 patients with objective responses after combined TACE and RT, 41 patients underwent surgery, including eight liver transplantations. The unweighted surgery group was younger and had a higher proportion of solitary tumors and unilateral vascular involvement. After adjustment, the 3-year overall survival (OS) rates were 61.0% and 28.6% in the surgery and non-surgery groups, respectively. The most important prognostic factor for OS was surgery (adjusted Cox hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.17 to 0.46; p < 0.001). Complete response after TACE and RT (vs. partial response) was also a significant prognostic factor for OS (adjusted HR, 0.41; 95% CI, 0.27 to 0.61; p < 0.001). There was no surgical mortality. Four patients (9.8%) required additional surgery due to bleeding or graft failure.
Conclusion
Hepatic resection was significantly associated with improved OS in patients who showed objective responses after receiving combined TACE and RT for HCC with MVI.

Citations

Citations to this article as recorded by

Multimodal deep learning model for predicting prognosis following radiotherapy-based combination therapy in unresectable hepatocellular carcinoma
Haoming Xia, Qizhen Huang, Ziyue Huang, Ziqi Zhou, Yongyi Zeng, Jingguang Ma, Xiangyu Fan, Yechong Huang, Yuexi Dong, Haitao Zhao, Gong Li, Jitao Wang, Shizhong Yang, Jiahong Dong
Cancer Letters.2026; 636: 218122. CrossRef

2,929 View
87 Download
1 Web of Science
1 Crossref

Rare cancer

Outcomes of Stereotactic Body Radiation Therapy for Large Uveal Melanoma: A Retrospective Analysis of Asian Population: Jong Won Park, Seowoong Jun, Ki Chang Keum, Christopher Seungkyu Lee, Kyung Hwan Kim; Cancer Res Treat. 2025;57(4):1218-1230. Published online December 31, 2024; DOI: https://doi.org/10.4143/crt.2024.580

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the clinical outcomes of stereotactic body radiation therapy (SBRT) in patients with large uveal melanoma (UM).
Materials and Methods
We conducted a retrospective review of 64 consecutive patients with UM treated with CyberKnife at Yonsei Cancer Center from September 2015 to October 2021. The median radiation dose was 60 Gy (range, 48 to 64 Gy) administered in four fractions every alternate day. The local failure-free rate (LFFR), distant metastasis-free rate (DMFR), progression-free survival (PFS), and overall survival (OS) were assessed using the Kaplan-Meier method and log-rank test. Cox regression analysis was performed to analyze the predictive factors affecting survival outcomes and the factors associated with vision loss.
Results
The median tumor diameter and height were 11.5 mm and 8.4 mm, respectively. After a median follow-up of 32.1 months (range, 4.9 to 89.9 months), the 3-year LFFR, DMFR, PFS, and OS were 89.5%, 70.5%, 65.5%, and 89.4%, respectively. Enucleation was performed in 13 (20.3%) patients, with three cases attributed to disease progression. A larger tumor diameter was associated with significantly worse DMFR (hazard ratio [HR], 1.35; p=0.015) and OS (HR, 1.49; p=0.026) in the multivariate analysis. Regarding visual prognosis, 41 patients (64.1%) had baseline visual acuity ≥ 20/200, but only four patients (6.3%) maintained visual acuity ≥ 20/200 by the final follow-up. Initial visual acuity ≥ 20/40 (HR, 0.45; p=0.030) was the single favorable significant factor predicting visual retention ≥ 20/200 in multivariate analysis.
Conclusion
SBRT using CyberKnife demonstrated a comparable local control rate to that observed in historical studies for patients with large UM. Distant metastasis and treatment-related ocular toxicity remain the limitations of this treatment.

Citations

Citations to this article as recorded by

Carbon Ion Versus Photon-based Stereotactic Ablative Radiation Therapy for Patients with Choroidal Melanoma
Jina Kim, Masaru Wakatsuki, Shuri Aoki, Jong Won Park, Nao Kobayashi, Ki Chang Keum, Hirokazu Makishima, Christopher Seungkyu Lee, Hitoshi Ishikawa, Kyung Hwan Kim
Advances in Radiation Oncology.2025; 10(12): 101915. CrossRef

3,986 View
100 Download
1 Web of Science
1 Crossref

Lung and Thoracic cancer

Upfront Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients with Brain Metastases from Non–Small Cell Lung Cancer: A Retrospective Analysis of a 10-Year Bi-institutional Experience: Myungsoo Kim, Jihye Cha, Hun Jung Kim, Woo Chul Kim, Jeongshim Lee; Cancer Res Treat. 2025;57(1):47-56. Published online July 3, 2024; DOI: https://doi.org/10.4143/crt.2024.223

Abstract PDF PubReader ePub

Purpose
Stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) are increasingly used as initial therapies for brain metastases (BM). We aimed to assess the outcomes of SRS/FSRT in patients aged ≥ 65 years who had 1-10 BM from non–small cell lung cancer (NSCLC).
Materials and Methods
We retrospectively reviewed 91 elderly NSCLC patients with 222 BM who were treated with SRS/FSRT at two institutions between 2010 and 2020. The primary endpoint was overall survival (OS) after SRS/FSRT. In addition, in-field local control (IFLC) within the treated field was evaluated. Statistical analysis was performed to identify the prognostic factors affecting OS and IFLC.
Results
During a median follow-up of 18 months, the median OS was 32 months. The 1- and 2-year survival rates were 69.8% and 56.1%, respectively. In multivariate analysis, the NSCLC-specific graded prognostic assessment (GPA) score (p=0.007) and administration of systemic therapy (p=0.039) were defined as prognosticators affecting OS. The median IFLC period was 31 months, and the 1- and 2-year IFLC rates were 75.9% and 57.6%, respectively. The total BM volume (p=0.042) significantly affected IFLC. No severe adverse events were reported after SRS/FSRT.
Conclusion
SRS/FSRT is an effective upfront treatment option for BM arising from NSCLC in elderly patients, with a good OS without severe side effects. Higher GPA score and active systemic treatment were associated with improved OS, indicating that elderly patients are significant candidates for SRS/FSRT.

Citations

Citations to this article as recorded by

Prognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer
Dayu Xu, Yechun Pang, Jinghan Qu, Jiuang Mao, Tiantian Guo, Shanshan Jiang, Yue Zhou, Li Chu, Xi Yang, Xiao Chu, Shengping Wang, Tong Tong, Zhengfei Zhu, Jianjiao Ni
Clinical and Translational Radiation Oncology.2025; 55: 101038. CrossRef
Prognostic Analysis of Lung Cancer With Brain Metastases in Elderly Patients: A Multicenter Retrospective Study
Anqi Li, Daqin Feng, Chang Liu, Chaojue Huang, Tang Li, Donggui Wei, Fangyi Wei, Muling Shen, Congzhi Qin, Shufang Deng, Hui Liang, Panlin Mo, Minhai Dong, Yongjia Yu, Lun Liang
AGING MEDICINE.2025; 8(6): 585. CrossRef

5,613 View
217 Download
2 Web of Science
2 Crossref

Clinical Effect of Endosonography on Overall Survival in Patients with Radiological N1 Non–Small Cell Lung Cancer: Bo-Guen Kim, Byeong-Ho Jeong, Goeun Park, Hong Kwan Kim, Young Mog Shim, Sun Hye Shin, Kyungjong Lee, Sang-Won Um, Hojoong Kim, Jong Ho Cho; Cancer Res Treat. 2024;56(2):502-512. Published online December 4, 2023; DOI: https://doi.org/10.4143/crt.2023.840

Abstract PDF Supplementary Material PubReader ePub: Purpose
It is unclear whether performing endosonography first in non–small cell lung cancer (NSCLC) patients with radiological N1 (rN1) has any advantages over surgery without nodal staging. We aimed to compare surgery without endosonography to performing endosonography first in rN1 on the overall survival (OS) of patients with NSCLC.
Materials and Methods
This is a retrospective analysis of patients with rN1 NSCLC between 2013 and 2019. Patients were divided into ‘no endosonography’ and ‘endosonography first’ groups. We investigated the effect of nodal staging through endosonography on OS using propensity score matching (PSM) and multivariable Cox proportional hazard regression analysis.
Results
In the no endosonography group, pathologic N2 occurred in 23.0% of patients. In the endosonography first group, endosonographic N2 and N3 occurred in 8.6% and 1.6% of patients, respectively. Additionally, 51 patients were pathologic N2 among 249 patients who underwent surgery and mediastinal lymph node dissection (MLND) in endosonography first group. After PSM, the 5-year OSs were 68.1% and 70.6% in the no endosonography and endosonography first groups, respectively. However, the 5-year OS was 80.2% in the subgroup who underwent surgery and MLND of the endosonography first group. Moreover, in patients receiving surgical resection with MLND, the endosonography first group tended to have a better OS than the no endosonography group in adjusted analysis using various models.
Conclusion
In rN1 NSCLC, preoperative endosonography shows better OS than surgery without endosonography. For patients with rN1 NSCLC who are candidates for surgery, preoperative endosonography may help improve survival through patient selection.

5,288 View
119 Download

Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma: Gowoon Yang, Kyung Hwan Kim, Chang Geol Lee, Min Hee Hong, Hye Ryun Kim, Yeona Cho, Hong In Yoon; Cancer Res Treat. 2024;56(1):115-124. Published online August 29, 2023; DOI: https://doi.org/10.4143/crt.2023.600

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to determine the role of local ablative radiotherapy (LART) in oligometastatic/oligoprogressive lung adenocarcinoma.
Materials and Methods
Patients (n=176) with oligometastatic lung adenocarcinoma treated with LART were identified, and those treated with LART at the initial diagnosis of synchronous oligometastatic disease (OMD group) or treated with LART when they presented with repeat oligoprogression (OPD group) were included.
Results
In the OMD group (n=54), the 1- and 3-year progression-free survival (PFS) were 50.9% and 22.5%, respectively, whereas the 1- and 3-year overall survival in the OPD group were 75.9% and 58.1%, respectively. Forty-one patients (75.9%) received LART at all gross disease sites. Tyrosine kinase inhibitor (TKI) use and all-metastatic site LART were significant predictors of higher PFS (p=0.018 and p=0.046, respectively). In patients treated with TKIs at the time of LART (n=23) and those treated with all-metastatic site LART, the 1-year PFS was 86.7%, while that of patients not treated with all-metastatic site LART was 37.5% (p=0.006). In the OPD group (n=122), 67.2% of the patients (n=82) maintained a systemic therapy regimen after LART. The cumulative incidence of changing systemic therapy was 39.6%, 62.9%, and 78.5% at 6 months, 1 year, and 2 years after LART, respectively.
Conclusion
Aggressive LART can be an option to improve survival in patients with oligometastatic disease. Patients with synchronous oligometastatic disease receiving TKI and all-metastatic site LART may have improved PFS. In patients with repeat oligoprogression, LART might potentially extend survival by delaying the need to change the systemic treatment regimen.

5,920 View
206 Download

Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry: Jeonghee Yun, Jong Ho Cho, Tae Hee Hong, Kyungmi Yang, Yong Chan Ahn, Hong Kwan Kim, Korean Association for Lung Cancer, Korea Central Cancer Registry; Cancer Res Treat. 2023;55(4):1171-1180. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2022.1581

Abstract PDF Supplementary Material PubReader ePub

Purpose
Stereotactic body radiotherapy (SBRT) had been increasingly recognized as a favorable alternative to surgical resection in patients with high risk for surgery. This study compared survival outcomes between sublobar resection (SLR) and SBRT for clinical stage I non–small cell lung cancer (NSCLC).
Materials and Methods
Data were obtained from the Korean Association of Lung Cancer Registry, a sampled nationwide database. This study retrospectively reviewed 382 patients with clinical stage I NSCLC who underwent curative SLR or SBRT from 2014 to 2016.
Results
Of the patients, 43 and 339 underwent SBRT and SLR, respectively. Patients in the SBRT group were older and had worse pulmonary function. The 3-year overall survival (OS) rate was significantly better in the SLR group compared with the SBRT group (86.6% vs. 57%, log-rank p < 0.001). However, after adjusting for age, sex, tumor size, pulmonary function, histology, smoking history, and adjuvant therapy, treatment modality was not an independent prognostic factor for survival (hazard ratio, 0.99; 95% confidence interval, 0.43 to 2.77; p=0.974). We performed subgroup analysis in the following high-risk populations: patients who were older than 75 years; patients who were older than 70 years and had diffusing capacity of lung for carbon monoxide ≤ 80%. In each subgroup, there were no differences in OS and recurrence-free survival between patients who underwent SLR and those who received SBRT.
Conclusion
In our study, there were no significant differences in terms of survival or recurrence between SBRT and SLR in medically compromised stage I NSCLC patients. Our findings suggest that SBRT could be considered as a potential treatment option for selected patients.

Citations

Citations to this article as recorded by

Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients
Stijn Vanstraelen, Kay See Tan, Prasad S. Adusumilli, Manjit S. Bains, Matthew J. Bott, Robert J. Downey, Daniel R. Gomez, Katherine D. Gray, James Huang, James M. Isbell, Daniela Molena, Bernard J. Park, Andreas Rimner, Valerie W. Rusch, Narek Shaverdian
Annals of Surgery.2026; 283(5): 807. CrossRef
Sublobar resection, stereotactic body radiotherapy, and thermal ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis
Shahar Adar, Alexandra Ádám, Tamara Balogh, Mátyás Rédei, Karen Krisztina Fazekas, Mátyás Paczkó, Nina Galdzytska, Marie Anne Engh, András Bibok, Gábor Zoltán Duray, Péter Hegyi, Dénes Balázs Horváthy
Lung Cancer.2026; 217: 109467. CrossRef
The limits of pooled evidence in early-stage NSCLC: are we comparing treatments or patients?
Peter S.N. van Rossum, Famke L. Schneiders, Suresh Senan
Lung Cancer.2026; : 109555. CrossRef
Surgery Versus Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer (NSCLC): A Comprehensive Review of Survival and Local Control Outcomes
Abdulrahman Bin Sumaida, Nandan M Shanbhag, Nadeem Pervez, Khalifa AlKaabi, Khalid Balaraj
Cureus.2025;[Epub] CrossRef
Surgery for all patients with T1N0 non-small cell lung cancer?
Claudia Pouypoudat, Sébastien Thureau, Nicolas Giraud, Yaniss Belaroussi, Étienne Martin
Cancer/Radiothérapie.2025; 29(5-6): 104683. CrossRef

7,280 View
219 Download
5 Web of Science
5 Crossref

Clinical Outcome of Stereotactic Body Radiotherapy in Patients with Early-Stage Lung Cancer with Ground-Glass Opacity Predominant Lesions: A Single Institution Experience: Jeong Yun Jang, Su Ssan Kim, Si Yeol Song, Young Seob Shin, Sei Won Lee, Wonjun Ji, Chang-Min Choi, Eun Kyung Choi; Cancer Res Treat. 2023;55(4):1181-1189. Published online March 21, 2023; DOI: https://doi.org/10.4143/crt.2022.1656

Abstract PDF Supplementary Material PubReader ePub

Purpose
The detection rate of early-stage lung cancer with ground-glass opacity (GGO) has increased, and stereotactic body radiotherapy (SBRT) has been suggested as an alternative to surgery in inoperable patients. However, reports on treatment results are limited. Therefore, we performed a retrospective study to investigate the clinical outcome after SBRT in patients with early-stage lung cancer with GGO-predominant tumor lesions at a single institution.
Materials and Methods
This study included 89 patients with 99 lesions who were treated with SBRT for lung cancer with GGO-predominant lesions that had a consolidation-to-tumor ratio of ≤0.5 at Asan Medical Center between July 2016 and July 2021. A median total dose of 56.0 Gy (range, 48.0–60.0) was delivered using 10.0–15.0 Gy per fraction.
Results
The overall follow-up period for the study was median 33.0 months (range, 9.9 to 65.9 months). There was 100% local control with no recurrences in any of the 99 treated lesions. Three patients had regional recurrences outside of the radiation field, and three had distant metastasis. The 1-year, 3-year, and 5-year overall survival rates were 100.0%, 91.6%, and 82.8%, respectively. Univariate analysis revealed that advanced age and a low level of diffusing capacity of the lungs for carbon monoxide were significantly associated with overall survival. There were no patients with grade ≥3 toxicity.
Conclusion
SBRT is a safe and effective treatment for patients with GGO-predominant lung cancer lesions and is likely to be considered as an alternative to surgery.

Citations

Citations to this article as recorded by

Prognostic analysis of helical tomotherapy stereotactic body radiotherapy in multiple primary or second primary lung cancers
Jintao Ma, Xiaohong Xu, Wenhan Huang, Yong Hu, Gang Chen, Jian He
BMC Cancer.2025;[Epub] CrossRef
Place de la radiothérapie en conditions stéréotaxiques dans les cancers bronchiques non à petites cellules localisés
Catherine Durdux, Aurélia Alati
Bulletin du Cancer.2025; 112(3): 3S31. CrossRef
Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis–1N0M0 Lung Cancer
Junki Fukuda, Hiroshi Doi, Atsushi Kono, Takaya Inagaki, Naoko Ishida Hamazawa, Saori Tatsuno Imamura, Takuya Uehara, Masahiro Inada, Kiyoshi Nakamatsu, Makoto Hosono, Kazunari Ishii, Yukinori Matsuo
Thoracic Cancer.2025;[Epub] CrossRef
Management of possible idiopathic inferior vena cava compression during stereotactic body radiation therapy for lung cancer
Shinya Neri, Yuma Ichikawa
BMJ Case Reports.2025; 18(8): e263832. CrossRef
European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer
Alessandro Brunelli, Georgia Hardavella, Rudolf M. Huber, Thierry Berghmans, Armin Frille, Maria Rodriguez, Ilona Tietzova, Lieven Depypere, Riccardo Asteggiano, Tim Batchelor, Adrien Costantini, Dirk De Ruysscher, Valerie Durieux, Corinne Faivre-Finn, Ma
European Respiratory Journal.2025; 66(5): 2500156. CrossRef
European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer
Alessandro Brunelli, Georgia Hardavella, Rudolf M Huber, Thierry Berghmans, Armin Frille, Maria Rodriguez, Ilona Tietzova, Lieven Depypere, Riccardo Asteggiano, Tim Batchelor, Adrien Costantini, Dirk De Ruysscher, Valerie Durieux, Corinne Faivre-Finn, Mar
European Journal of Cardio-Thoracic Surgery.2025;[Epub] CrossRef
Recent Advancements in Minimally Invasive Surgery for Early Stage Non-Small Cell Lung Cancer: A Narrative Review
Jibran Ahmad Khan, Ibrahem Albalkhi, Sarah Garatli, Marcello Migliore
Journal of Clinical Medicine.2024; 13(11): 3354. CrossRef
The clinical effect of thoracoscopic segmentectomy in the treatment of lung malignancies less than 2CM in diameter
Yafeng Zhang, Renzhong Shi, Xiaoming Xia, Kaiyao Zhang
Journal of Cardiothoracic Surgery.2024;[Epub] CrossRef
Impact of ground-glass component on prognosis in early-stage lung cancer treated with stereotactic body radiotherapy via Helical Tomotherapy
Jintao Ma, Shaonan Fan, Wenhan Huang, Xiaohong Xu, Yong Hu, Jian He
Radiation Oncology.2024;[Epub] CrossRef

8,190 View
242 Download
12 Web of Science
9 Crossref

General

Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis: Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Eui Kyu Chie, Yong Chan Ahn, The Oligometastasis Working Group, Korea Cancer Association; Cancer Res Treat. 2022;54(4):953-969. Published online August 16, 2022; DOI: https://doi.org/10.4143/crt.2022.329

Abstract PDF Supplementary Material PubReader ePub

Purpose
We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method.
Materials and Methods
Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controlled trials comparing outcomes of LCT versus a control group. Primary endpoints are overall survival (OS) and progression-free survival (PFS).
Results
A total of 54 studies involving 7,242 patients were included. Pooled analyses showed that the LCT arm could achieve improved OS with pooled odds ratio of 2.896 (95% confidence interval [CI], 2.377 to 3.528; p < 0.001). Regarding PFS, pooled analyses showed pooled odds ratio of 3.045 (95% CI, 2.356 to 3.937; p < 0.001) in favor of the LCT arm. In the subgroup analyses including the studies with reliable comparability (e.g. randomized studies or intentionally matched studies without significant favorable prognosticator in LCT arms), pooled odds ratio was 2.548 (95% CI, 1.808 to 3.591; p < 0.001) favoring the LCT arm regarding OS. Regarding PFS, pooled OR was 2.656 (95% CI, 1.713 to 4.120; p < 0.001) which also favored the LCT arm. Subgroup analyses limited to the randomized controlled trials (RCT) were also performed and pooled odds ratios on OS and PFS were 1.535 (95% CI, 1.082 to 2.177; p=0.016) and 1.668 (95% CI, 1.187 to 2.344; p=0.003). The rates of grade ≥ 3 complications related to LCT was mostly low (< 10%) and not significantly higher compared to the control arm.
Conclusion
Pooled analyses results of all included studies, selected studies with reliable comparability, and RCT’s demonstrated the survival benefit of LCT. These consistent results suggest that LCT was beneficial to the patients with oligometastasis.

Citations

Citations to this article as recorded by

Impact of TGF-β1 on tumor immune microenvironment and prognosis in colorectal liver oligometastasis
Song Wang, Jiahua He, Yuanbin Liao, Weihao Li, Weili Zhang, Da Kang, Weifeng Wang, Ruowei Wang, Chi Zhou, Junzhong Lin, Leen Liao, Jianhong Peng, Yuguang Lin
Cancer Treatment and Research Communications.2026; 46: 101059. CrossRef
Long-term Survival after Surgery in a Patient with Small Bowel Metastasis of Hepatocellular Carcinoma: A Case Report and Literature Review
Je Seong Kim, Won Jae Lee, Chae June Lim, Young Eun Seo, Chan Muk Im, Hyung Hoon Oh, Ki-Hyun Kim, Young Eun Joo
Journal of Digestive Cancer Research.2026; 14(1): 115. CrossRef
Continuation of first-line therapy with radiotherapy for oligoprogression versus early switch to second-line therapy in oligoprogressive hepatocellular carcinoma (CROSS): study protocol of a multicentre, randomised, controlled, open-label, phase III trial
Haohua Wang, Fang Shi, Xiang Zhang, Kunli Zhu, Shumei Jiang, Rui Feng, Xue Dou, Lei Xu, Jinbo Yue
BMJ Open.2026; 16(6): e118739. CrossRef
Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
Cancer Research and Treatment.2025; 57(1): 11. CrossRef
The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer
Mara B. Antonoff, Kyle G. Mitchell, Samuel S. Kim, Hai V. Salfity, Svetlana Kotova, Robert Taylor Ripley, Alfonso L. Neri, Pallavi Sood, Saumil G. Gandhi, Yasir Y. Elamin, Jessica S. Donington, David R. Jones, Elizabeth A. David, Stephen G. Swisher, Isabe
The Annals of Thoracic Surgery.2025; 119(3): 495. CrossRef
Maintaining First-Line Therapy Plus Radiation Therapy May Prolong Progression-Free Survival and Delay Second-Line Therapy for Oligoprogressive Hepatocellular Carcinoma
Boyu Leng, Haohua Wang, Yunfan Ge, Xiaoli Sun, Pingping Dong, Xinzhe Dong, Xuezhang Duan, Quan Wang, Yaoxiong Xia, Lijuan Ding, Honghai Dai, Tianxing Liu, Fang Shi, Xiang Zhang, Jinbo Yue
International Journal of Radiation Oncology*Biology*Physics.2025; 122(2): 325. CrossRef
The patterns of systemic metastasis in major salivary gland cancer and therapeutic implications
Subi Oh, Younghac Kim, Hyojun Kim, Eunhye Kim, Sook-young Woo, Nayeon Choi, Junhun Cho, Dongryul Oh, Yong-Chan Ahn, Sehhoon Park, Myung-Ju Ahn, Han-Sin Jeong
Oral Oncology.2025; 164: 107258. CrossRef
Surgery for Stage IV Disease—Is It Prime Time Yet?
Marianna V. Papageorge, Mara B. Antonoff
Surgical Oncology Clinics of North America.2025; 34(4): 489. CrossRef
Oligometastatic pancreatic cancer: current state of management and emerging therapies
Andrii Khomiak, Nicole B Balmaceda, Sumaya A Ghaffar, Christopher H Lieu, Marco Del Chiaro, Wells A Messersmith, Robert W Lentz
The Oncologist.2025;[Epub] CrossRef
Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review
César P. Ramírez-Plaza, Marta Roldón-Golet, José A. Pérez-Daga, Fernando Pereira-Pérez
Clinical and Translational Oncology.2025; 28(3): 789. CrossRef
Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma
Gowoon Yang, Kyung Hwan Kim, Chang Geol Lee, Min Hee Hong, Hye Ryun Kim, Yeona Cho, Hong In Yoon
Cancer Research and Treatment.2024; 56(1): 115. CrossRef
MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters
Mette van Overeem Felter, Pia Krause Møller, Mirjana Josipovic, Susanne Nørring Bekke, Uffe Bernchou, Eva Serup-Hansen, Kasper Madsen, Parag J. Parikh, Joshua Kim, Poul Geertsen, Claus P. Behrens, Ivan R. Vogelius, Mette Pøhl, Tine Schytte, Gitte Fredberg
Radiotherapy and Oncology.2024; 192: 110090. CrossRef
Clinical implication of neck dissection for metastatic lymph nodes originating from non-head and neck regions
Min Ji Kim, So Hee Kang, MinSu Kwon, Young Ho Jung, Seung-Ho Choi, Soon Yuhl Nam, Yoon Se Lee
Acta Oto-Laryngologica.2024; 144(2): 153. CrossRef
Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability
Shruti Koti, Lyudmyla Demyan, Gary Deutsch, Matthew Weiss
Annals of Surgical Oncology.2024; 31(6): 4031. CrossRef
Radiation Oncologists’ Perspectives on Oligometastatic Disease: A Korean Survey Study
Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Ah Ram Chang, Eui Kyu Chie, Yong Chan Ahn
Cancer Research and Treatment.2024; 56(2): 414. CrossRef
Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group
Gyu Sang Yoo, Sunmin Park, Chai Hong Rim, Won Kyung Cho, Ah Ram Chang, Young Seok Kim, Yong Chan Ahn, Eui Kyu Chie
Current Oncology.2024; 31(6): 3239. CrossRef
Local Ablative Therapy Combined With Pembrolizumab in Patients With Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis
Hye In Lee, Eun Kyung Choi, Su Ssan Kim, Young Seob Shin, Junhee Park, Chang-Min Choi, Shinkyo Yoon, Hyeong Ryul Kim, Young Hyun Cho, Si Yeol Song
International Journal of Radiation Oncology*Biology*Physics.2024; 120(3): 698. CrossRef
Retrospective Analysis of Efficacy and Toxicity of Stereotactic Body Radiotherapy and Surgical Resection of Adrenal Metastases from Solid Tumors
Jamie Lütscher, Hans Gelpke, Adrian Zehnder, Laetitia Mauti, Christian Padevit, Hubert John, Nidar Batifi, Daniel Rudolf Zwahlen, Robert Förster, Christina Schröder
Cancers.2024; 16(15): 2655. CrossRef
A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation
Hanseung Kang, Woohyeon Do, Yong Chan Ahn, Eui Kyu Chie, Chai Hong Rim
European Journal of Cancer.2024; 212: 115043. CrossRef
Oligometastasis: More Lessons to Be Learned
Kyung Hwan Kim, Yong Chan Ahn
Cancer Research and Treatment.2023; 55(1): 1. CrossRef
Top Ten Lessons Learned from Trials in Oligometastatic Cancers
Vivian S. Tan, David A. Palma
Cancer Research and Treatment.2023; 55(1): 5. CrossRef
Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer
Rongxin Liao, Kehong Chen, Jinjin Li, Hengqiu He, Guangming Yi, Mingfeng Huang, Rongrong Chen, Lu Shen, Xiaoyue Zhang, Zaicheng Xu, Zhenzhou Yang, Yuan Peng
Cancer Research and Treatment.2023; 55(3): 814. CrossRef
Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee
Cancer Research and Treatment.2023; 55(3): 707. CrossRef
Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn
Cancer Research and Treatment.2023; 55(4): 1063. CrossRef
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
Radiation Oncology.2023;[Epub] CrossRef
Oligometastasis: Expansion of Curative Treatments in the Field of Oncology
Ah Reum Lim, Chai Hong Rim
Medicina.2023; 59(11): 1934. CrossRef
Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment
Dae Ho Lee
Cancer Research and Treatment.2022; 54(4): 951. CrossRef

10,460 View
360 Download
30 Web of Science
27 Crossref

Gynecologic cancer

Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study: Se Ik Kim, Hyunji Lim, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Maria Lee; Cancer Res Treat. 2023;55(1):245-257. Published online July 19, 2022; DOI: https://doi.org/10.4143/crt.2022.232

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to investigate the impact of BRCA1/2 mutational status on survival outcomes in patients with platinum-sensitive relapsed (PSR) epithelial ovarian cancer (EOC).
Materials and Methods
We retrospectively identified patients who received secondary treatment for PSR EOC at our institution between January 2007 and June 2021 and who underwent BRCA1/2 gene testing by either germline or somatic methods. The association between BRCA1/2 mutational status and survival outcomes was evaluated. Both secondary cytoreductive surgery (CRS) and maintenance therapy were stratified considering real-world clinical practice.
Results
Of 262 patients, 91 (34.7%) and 171 (65.3%) were assigned to BRCA1/2 mutation and wild-type groups, respectively. The two groups had similar proportions of patients undergoing secondary CRS (26.4% vs. 32.7%, p=0.286) and maintenance therapy (54.9% vs. 46.2%, p=0.178). Overall, no differences in progression-free survival (PFS; median, 19.7 vs. 15.1 months, p=0.120) and overall survival (OS; p=0.400) were observed between the two groups. In multivariate analyses, BRCA1/2 mutational status was not associated with PFS (adjusted hazard ratio, 0.816; 95% confidence interval, 0.596 to 1.119; p=0.207). BRCA1/2 mutational status did not affect PFS among patients who underwent secondary CRS (n=80) and among those who did not (n=182) (p=0.074 and p=0.222, respectively). PFS did not differ in the BRCA1/2 mutational status among the patients who received bevacizumab maintenance (n=90, p=0.992).
Conclusion
In this real-world evidence study, BRCA1/2 mutational status itself was not associated with PFS and OS in PSR EOC, which was consistent with whether secondary CRS or not and with bevacizumab maintenance.

7,073 View
170 Download

Breast cancer

Effect of Postoperative Radiotherapy after Primary Tumor Resection in De Novo Stage IV Breast Cancer: A Multicenter Retrospective Study (KROG 19-02): Yeon Joo Kim, Yeon-Joo Kim, Yong Bae Kim, Ik Jae Lee, Jeanny Kwon, Kyubo Kim, Jihye Cha, Myungsoo Kim, In Young Jo, Jung Hoon Kim, Jaehyeon Park, Jin Hee Kim, Juree Kim, Kyung Hwan Shin, Su Ssan Kim; Cancer Res Treat. 2022;54(2):478-487. Published online July 12, 2021; DOI: https://doi.org/10.4143/crt.2021.632

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the impact of postoperative radiotherapy (PORT) in de novo metastatic breast cancer (dnMBC) patients undergoing planned primary tumor resection (PTR) and to identify the subgroup of patients who would most benefit from PORT.
Materials and Methods
This study enrolled 426 patients with dnMBC administered PTR alone or with PORT. The primary and secondary outcomes were overall and progression-free survival (OS and PFS), respectively.
Results
The median follow-up time was 53.7 months (range, 3.1 to 194.4). The 5-year OS and PFS rates were 73.2% and 32.0%, respectively. For OS, clinical T3/4 category, triple-negative breast cancer (TNBC), postoperative chemotherapy alone were significantly poor prognostic factors, and administration of PORT failed to show its significance. Regarding PFS, PORT was a favorable prognostic factor (hazard ratio, 0.64; 95% confidence interval, 0.50 to 0.82; p < 0.001), in addition to T1/2 category, ≤ 5 metastases, and non-TNBC. According to the multivariate analyses of OS in the PORT group, we divided the patients into three groups (group 1, T1/2 and non-TNBC [n=193]; group 2, T3/4 and non-TNBC [n=171]; and group 3, TNBC [n=49]), and evaluated the effect of PORT. Although PORT had no significance for OS in all subgroups, it was a significant factor for good prognosis regarding PFS in groups 1 and 2, not in group 3.
Conclusion
PORT was associated with a significantly better PFS in patients with dnMBC who underwent PTR. Patients with clinical T1/2 category and non-TNBC benefited most from PORT, while those with TNBC showed little benefit.

Citations

Citations to this article as recorded by

Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study
Pingchuan Li, Lineng Wei, Yinan Ji, Huawei Yang
Technology in Cancer Research & Treatment.2025;[Epub] CrossRef
Survival Between Mastectomy and Breast-Conserving Surgery in De Novo Metastatic Breast Cancer: A Propensity Score-Matched Study
Yi-Yan Hong, Hong-Liang Zhan, Guan-Qiao Li, Qiu-Yan Chen, San-Gang Wu, Fu-Xing Zhang
Journal of Investigative Surgery.2025;[Epub] CrossRef
Postoperative radiotherapy for stage IV breast cancer following primary tumor removal: Systematic review and meta-analysis
Anna Maria Merlotti, Stefania Martini, Anna Maria Vandone, Riccardo Bonomi, Salvatore Dario Solla, Francesco Olivero, Lavinia Spinelli, Paola Critelli, Luca Gianello, Riccardo Vigna Taglianti, Grazia Sciancalepore, Alessio Garetto, Gianmauro Numico, Richa
Tumori Journal.2025; 111(6): 463. CrossRef
Locoregional radiation therapy as a stage of complex stage for de novo metastatic breast cancer
E. V. Timoshkina, S. I. Tkachev, O. P. Trofimova, M. V. Chernykh, Yu. I. Pryamikova
Tumors of female reproductive system.2025; 21(3): 16. CrossRef
Letter to the editor for the article“Tumor margin irregularity degree is an important preoperative predictor of adverse pathology for clinical T1/2 renal cell carcinoma and the construction of predictive model”
Yaping Miao, Lexin Wang, Ping Chen, Jiaan Lu, Guanhu Yang, Hao Chi
World Journal of Urology.2024;[Epub] CrossRef
The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer
Tian Yang, Xiaorong Zhong, Jun Wang, Zhongzheng Xiang, Yuanyuan Zeng, Siting Yu, Zelei Dai, Ningyue Xu, Ting Luo, Lei Liu
Cancer Medicine.2023; 12(7): 8112. CrossRef
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
Radiation Oncology.2023;[Epub] CrossRef
Machine learning predicts the prognosis of breast cancer patients with initial bone metastases
Chaofan Li, Mengjie Liu, Jia Li, Weiwei Wang, Cong Feng, Yifan Cai, Fei Wu, Xixi Zhao, Chong Du, Yinbin Zhang, Yusheng Wang, Shuqun Zhang, Jingkun Qu
Frontiers in Public Health.2022;[Epub] CrossRef
Factors Influencing Prognosis in Patients with De Novo Stage IV Breast Cancer: A Systematic Review and Meta-Analysis
Meilin Zhang, Zining Jin, Yingying Xu, Bo Chen, Jian Song, Muyao Li, Feng Jin, Ang Zheng
SSRN Electronic Journal .2022;[Epub] CrossRef

10,499 View
181 Download
7 Web of Science
9 Crossref

Head and Neck cancer

Radiotherapy versus Surgery in Early-Stage HPV-Positive Oropharyngeal Cancer: Dong-Yun Kim, Hong-Gyun Wu, Jin Ho Kim, Joo Ho Lee, Soon-Hyun Ahn, Eun-Jae Chung, Keun-Yong Eom, Young Ho Jung, Woo-Jin Jeong, Tack-Kyun Kwon, Suzy Kim, Chan Woo Wee; Cancer Res Treat. 2022;54(2):406-416. Published online June 23, 2021; DOI: https://doi.org/10.4143/crt.2021.441

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to compare the outcomes of primary radiotherapy (RT) versus surgery in early-stage human papilloma virus–positive oropharyngeal squamous cell carcinoma (hpv+OPC), and investigate the preoperative clinical factors that can predict the requirement for postoperative adjuvant treatment.
Materials and Methods
This multicenter study included 166 patients with American Joint Committee on Cancer 8th edition-Stages I-II hpv+OPC. Sixty (36.1%) and 106 (63.9%) patients underwent primary (concurrent chemo)radiotherapy [(CC)RT] and surgery, respectively. Seventy-eight patients (73.6%) in the surgery group received postoperative (CC)RT.
Results
With a median follow-up of 45.6 months for survivors, the 2-year overall survival (OS), progression-free survival (PFS), and locoregional control (LC) for RT/surgery were 97.8%/96.4%, 91.1%/92.0%, and 92.9%/93.3%, respectively. In multivariate analyses, patients with synchronous radiologic extranodal extension and conglomeration (ENEcong) of metastatic lymph nodes (LNs) showed significantly poorer OS (p=0.047), PFS (p=0.001), and LC (p=0.003). In patients undergoing primary surgery, two or more clinically positive LN metastases (odds ratio [OR], 5.15; p=0.004) and LN metastases with ENEcong (OR, 3.75; p=0.009) were predictors of postoperative chemoradiotherapy. No patient in the primary RT group demonstrated late severe toxicity whereas three (2.8%), one (0.9%), and one (0.9%) patient in the surgery group showed grade 3 dysphagia, grade 3 xerostomia, and fatal oral cavity bleeding.
Conclusion
We found no differences in OS, PFS, and LC between upfront RT and surgery in stage I-II hpv+OPC which warrants comparison through a prospective trial in the treatment de-escalation era. However, most early-stage hpv+OPC patients undergoing surgery received adjuvant (CC)RT. Pretreatment LN findings were prognostic and predictive for adjuvant treatment.

Citations

Citations to this article as recorded by

Does Smoking Influence Outcomes in Human Papillomavirus—Associated Oropharyngeal Cancer Treated with Transoral Robotic Surgery?
Jane Y. Tong, Vera Bzhilyanskaya, Jason K. Molitoris, Matthew J. Ferris, Ranee Mehra, Kelly Moyer, Jeffrey Wolf, Rodney Taylor, Kyle M. Hatten
Otolaryngology–Head and Neck Surgery.2026; 174(4): 1003. CrossRef
Content of nuclear transcription factor NF-kB in blood serum of patients with squamous cell cancer of the head and neck in the dynamics of accelerated radiation therapy with radiomodifiers
N.A. Mitriaieva, L.V. Grebinyk, S.V. Artiukh, V.P. Starenkyi
Український радіологічний та онкологічний журнал.2026; 34(2): 187. CrossRef
Definitive radio(chemo)therapy versus upfront surgery in the treatment of HPV-related localized or locally advanced oropharyngeal squamous cell carcinoma
Jérémy Baude, Caroline Guigou, David Thibouw, Noémie Vulquin, Mireille Folia, Guillaume Constantin, Jihane Boustani, Christian Duvillard, Sylvain Ladoire, Gilles Truc, Aurélie Bertaut, Cédric Chevalier, Scott M. Langevin
PLOS ONE.2024; 19(7): e0307658. CrossRef
INFLUENCE OF CONFORMAL RADIOTHERAPY IN COMBINATION WITH RADIOMODIFIERS ON THE CONTENT OF VEGF, COX-2, AND PGE-2 IN BLOOD SERUM OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA
N. MITRYAYEVA, L. GREBINYK, S. ARTIUKH, N. BILOZOR, V. STARENKIY
Experimental Oncology.2024; 46(3): 253. CrossRef
Assessment of Radiologic Extranodal Extension Using Combinatorial Analysis of Nodal Margin Breakdown and Metastatic Burden in Oropharyngeal Cancer
Sungryeal Kim, Hannah Park, Se Hyun Yeou, Jin Roh, Yoo Seob Shin, Chul-Ho Kim, Eun Ju Ha, Jeon Yeob Jang
Cancers.2023; 15(13): 3276. CrossRef
Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review)
Chun Wei, Xiaojun Lan, Maona Qiu, Ran Cui, Qiuxia Fu, Shafiu Umar Shinge, Tobias Muluh, Ou Jiang
Oncology Letters.2023;[Epub] CrossRef

11,743 View
245 Download
4 Web of Science
6 Crossref

Oncological and Functional Outcomes of Larynx-preserving Surgery for Hypopharyngeal Cancer: A Comparison with Definitive Radiation-based Treatment: Donghyeok Kim, Nalee Kim, Sungmin Koh, Man Ki Chung, Young-Ik Son, Dongryul Oh, Han-Sin Jeong, Yong Chan Ahn; Cancer Res Treat. 2022;54(1):84-95. Published online March 26, 2021; DOI: https://doi.org/10.4143/crt.2020.1197

Abstract PDF Supplementary Material PubReader ePub

Purpose
Larynx-preserving surgery (LPS) have recently gained popularity and achieved comparable oncologic outcomes to conventional radical surgery for localized hypopharyngeal cancer (HPC). In the current study, the role of LPS has been assessed thoroughly in comparison with upfront radiation therapy (RT).
Materials and Methods
We retrospectively reviewed 185 candidates for LPS with cT1-2 disease; 59 patients underwent upfront LPS while 126 patients received upfront RT, respectively. Oncological and functional outcomes were investigated and compared.
Results
Following LPS, safe margin (≥ 5 mm) was achieved in 37.3% of patients. Overall, better clinical outcomes at 5 years were achieved following upfront LPS than those following upfront RT: overall survival (OS) (72.7% vs. 59.0%, p=0.045), disease-free survival (DFS) (59.8% vs. 45.0%, p=0.039), and functional laryngeal preservation (100% vs. 89.7%, p=0.010). Although similar outcomes were observed in patients with cT1 disease, better 5-year DFS was achieved following upfront LPS in patients with cT2 disease (57.0% vs. 36.4%, p=0.023) by virtue of better local control. Despite frequent cN2-3 disease in upfront LPS group, comparable outcomes were observed between upfront RT and LPS group. However, multivariable analyses revealed that performance status and double primary cancer diagnosed within 6 months of HPC diagnosis affected OS significantly, while treatment modality per se did not.
Conclusion
Although upfront LPS could provide better local control than upfront RT in patients with cT2 disease, overall outcomes were comparable following either modality. Treatment selection of larynx-preserving approach for HPC should be individualized based on tumor and patient factors.

Citations

Citations to this article as recorded by

Radiotherapy with or without chemotherapy for T2N0 hypopharyngeal cancer: an analysis of the head and neck cancer registry of Japan
Ari Nishimura, Naoki Fukuda, Daisuke Kawakita, Megumi Kitayama, Ken-ichi Nibu, Seiichi Yoshimoto, Hirokazu Uemura, Tadashi Kitahara
International Journal of Clinical Oncology.2026; 31(2): 328. CrossRef
Comparison of induction chemotherapy followed by concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by surgery and (chemo)radiotherapy in locoregionally advanced hypopharyngeal carcinoma: a prospective cohort study
Da-wei Zhao, Shi-rui Li, Fei Yang, Xiong-fang Guo, Xiao-zhe Sun, Ling Li, Su-cheng Tan, Jin-yang Qin, Ya-jing Qu, Zhong-qiu Wang, Lin Ma, Pei-guo Wang
Clinical and Translational Oncology.2026;[Epub] CrossRef
Guidelines for the Treatment of Laryngeal Cancer from the Korean Society of Head and Neck Surgery
Jeon Yeob Jang, Geun-Jeon Kim, Sang-Yeon Kim, Min-Su Kim, Dong Kun Lee, Minsu Kwon, Dongbin Ahn, Myung Jin Ban, Young Kang, Ho-Ryun Won, Jae Won Chang, Dong Won Lee, Ki Nam Park, Yeon Soo Kim, Ah Ra Jung, Jungirl Seok, Hye Ran Lee, Sung-Chan Shin, Chang M
Clinical and Experimental Otorhinolaryngology.2025; 18(2): 89. CrossRef
A Comparative Study of Initiated Chemotherapy Versus Initiated Surgery Combined with Primary-Radiotherapy in Locoregionally Advanced Hypopharyngeal Carcinoma
D.-w. Zhao, H.-y. Jiang, W.-j. Fan, L.-l. Meng, Y.-j. Qu, G.-b. Ren, X.-f. Guo, C.-l. Liu, B.-n. Cai, P.-g. Wang, L. Ma
Clinical Oncology.2025; 44: 103890. CrossRef
A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal
Mihaela Iuliana Ciortan (Sirbu), Maria Alina Marin, Doina Chioran, Iasmina-Alexandra Predescu, Nicolae Constantin Balica, Sergio Liga, Mircea Rivis, Ştefania Dinu, Şerban Talpoş
Current Oncology.2025; 32(10): 572. CrossRef
In Reply to Liu and Luo
Kangpyo Kim, Yong Chan Ahn
International Journal of Radiation Oncology*Biology*Physics.2024; 118(1): 308. CrossRef
The role and clinical significance of microRNA-29a-3p in the development of hypopharyngeal carcinoma
Tao Liu, Detao Ding, Wei Wang, Yungang Wu, Dengdian Ma, Miaomiao Liu, Ziqiao Tan, Jing Yao, Xiaoyu Li
Brazilian Journal of Otorhinolaryngology.2023; 89(3): 401. CrossRef
Survival and swallowing function outcome impact factors analysis of surgery-oriented comprehensive treatment for hypopharyngeal cancer in a series of 122 patients
Wan-Xin Li, Yan-Bo Dong, Cheng Lu, Patrick J. Bradley, Liang-Fa Liu
Ear, Nose & Throat Journal.2022; 101(8): 532. CrossRef

11,204 View
188 Download
9 Web of Science
8 Crossref

Lung Cancer

Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population: Ho Cheol Kim, Wonjun Ji, Jae Cheol Lee, Hyeong Ryul Kim, Si Yeol Song, Chang-Min Choi, Korean Association for Lung Cancer, Korea Central Cancer Registry; Cancer Res Treat. 2021;53(4):1033-1041. Published online February 16, 2021; DOI: https://doi.org/10.4143/crt.2020.1350

Abstract PDF Supplementary Material PubReader ePub

Purpose
The optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) remains controversial. This study aimed to investigate prognostic factors and clinical outcome in stage III NSCLC using real-world clinical data in the Korean population.
Materials and Methods
Among 8,110 patients with lung cancer selected from 52 hospitals in Korea during 2014-2016, only patients with stage III NSCLC were recruited and analyzed. A standardized protocol was used to collect clinical information and cox proportional hazards models were used to identify risk factors for mortality.
Results
A total of 1,383 patients (46.5% had squamous cell carcinoma and 40.9% had adenocarcinoma) with stage III NSCLC were enrolled, and their median age was 70 years. Regarding clinical stage, 548 patients (39.6%) had stage IIIA, 517 (37.4%) had stage IIIB, and 318 (23.0%) had stage IIIC. Pertaining to the initial treatment method, the surgery group (median survival period: 36 months) showed better survival outcomes than the non-surgical treatment group (median survival period: 18 months, p=0.001) in patients with stage IIIA. Moreover, among patients with stage IIIB and stage IIIC, those who received concurrent chemotherapy and radiation therapy (CCRT, median survival period: 24 months) showed better survival outcomes than those who received chemotherapy (median survival period: 11 months), or radiation therapy (median survival period: 10 months, p<0.001).
Conclusion
While surgery might be feasible as the initial treatment option in patients with stage IIIA NSCLC, CCRT showed a beneficial role in patients with stage IIIB and IIIC NSCLC.

Citations

Citations to this article as recorded by

Combining the prognostic values of entropy-based heterogeneity features from 18F-fluorodeoxyglucose PET and transmission computed tomography using machine learning in patients with lung adenocarcinoma undergoing curative surgery
Kun-Han Lue, Yu-Hung Chen, Sung-Chao Chu, Chih-Bin Lin, Bee-Song Chang, Pau-Yuan Chang, Shu-Hsin Liu
Nuclear Medicine Communications.2026; 47(4): 479. CrossRef
Development and validation of a novel nomogram model for predicting postoperative survival of T4N0M0 NSCLC: a population-based survival analysis
Tianjian Lu, Nan Chen, Zhe Wang, Weiping Lu
International Journal of Surgery.2026; 112(1): 1139. CrossRef
A long-term survival prediction model for non-small cell lung cancer based on blood inflammatory biomarkers
Yuxia Du, Weihong Qiu, Fei He, Zhibin Zhou, Weimin Ye
Discover Oncology.2026;[Epub] CrossRef
Development and validation of a nomogram for predicting overall survival in primary pulmonary lymphoepithelial carcinoma: a multicenter, large population-based study
Liqiang Wang, Chulan Zhan, Qiying Huang, Haonan Gao, Tong Lin, Jianhui Wu, Jili Zhuang, Xinqing Lin, Maolin Zhou, Shuxi Zhuo, Qingchuang Lin, Lingliang Huang, Ni Sun, Ying Chen, Xiaohong Xie, Chengzhi Zhou
European Journal of Medical Research.2026;[Epub] CrossRef
Incidence Patterns and Prognostic Impact of Lung‐Involving Multiple Primary Cancers: A 10‐Year Hospital‐Based Cohort Study
Hayoung Kim, Jin‐Hee Kwon, Heyjin Kim, Jin Kyung Lee, Young Jun Hong, Hye‐Ryoun Kim
Thoracic Cancer.2026;[Epub] CrossRef
The impact of sarcopenia on short-term efficacy, toxic and adverse reactions, and prognosis in patients with non-small cell lung cancer undergoing concurrent chemoradiotherapy
Yin Yuan, Zhao Yu, Yanchen Ma, Kaining Wang, Jianming Ding, Zelai He, Gengming Wang
Frontiers in Nutrition.2026;[Epub] CrossRef
The value of 18F-FDG PET/CT combined with 3D quantitative technology and clinicopathological features in predicting prognosis of NSCLC
Yuling Su, Siwen Qiu, Jinyu Wang
Frontiers in Oncology.2025;[Epub] CrossRef
Impact of tumor size by clinical N subclassification and histology in trimodality-treated N2 non-small cell lung cancer
Junghee Lee, Jin Lee, Yun Soo Hong, Genehee Lee, Jiyoun Park, Yeong Jeong Jeon, Seong-Yong Park, Jong Ho Cho, Yong Soo Choi, Jhingook Kim, Young Mog Shim, Eliseo Guallar, Juhee Cho, Hong Kwan Kim
Scientific Reports.2025;[Epub] CrossRef
Development and evaluation of tumor-targeting curcumin-loaded magnetic nanoparticles based on PEG-PLGA and transferrin for anti-lung cancer therapy
Gengsheng Shi, Wenqin Yin, Jing Luo, Song Lin, Linluo Zhang, Yuan He, Hui Ding
Materials Today Communications.2025; 47: 113050. CrossRef
Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
Cancer Medicine.2024;[Epub] CrossRef
Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data
Jeong Yun Jang, Si Yeol Song, Young Seob Shin, Ha Un Kim, Eun Kyung Choi, Sang-We Kim, Jae Cheol Lee, Dae Ho Lee, Chang-Min Choi, Shinkyo Yoon, Su Ssan Kim
Cancer Research and Treatment.2024; 56(3): 785. CrossRef
Risk factors in depression in oncology patients. Dr. Julio Villacreses Colmont Hospital
Mayra Viviana Zambrano Escobar, Julia Teresa Espinel García
Seminars in Medical Writing and Education.2024; 3: 660. CrossRef
Glucose metabolic heterogeneity correlates with pathological features and improves survival stratification of resectable lung adenocarcinoma
Yu-Hung Chen, Yen-Chang Chen, Kun-Han Lue, Sung-Chao Chu, Bee-Song Chang, Ling-Yi Wang, Ming-Hsun Li, Chih-Bin Lin
Annals of Nuclear Medicine.2023; 37(2): 139. CrossRef
The combined tumor-nodal glycolytic entropy improves survival stratification in nonsmall cell lung cancer with locoregional disease
Yu-Hung Chen, Kun-Han Lue, Sung-Chao Chu, Bee-Song Chang, Chih-Bin Lin
Nuclear Medicine Communications.2023; 44(1): 100. CrossRef
Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis
Yong-Jin Park, Yunjoo Im, O. Jung Kwon, Joungho Han, Myung-Ju Ahn, Jhingook Kim, Sang-Won Um, Joon Young Choi
Scientific Reports.2023;[Epub] CrossRef
A Propensity-Matched Retrospective Comparative Study with Historical Control to Determine the Real-World Effectiveness of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer
Cheol-Kyu Park, Nakyung Jeon, Hwa-Kyung Park, Hyung-Joo Oh, Young-Chul Kim, Ha-Lim Jeon, Yong-Hyub Kim, Sung-Ja Ahn, In-Jae Oh
Cancers.2023; 15(5): 1606. CrossRef
Association between clinical outcomes and local treatment in stage IV non‐small cell lung cancer patients with single extrathoracic metastasis
Jeong Uk Lim, Hye Seon Kang, Ah Young Shin, Chang Dong Yeo, Chan Kwon Park, Sang Haak Lee, Seung Joon Kim
Thoracic Cancer.2022; 13(9): 1349. CrossRef
Conversion therapy from unresectable stage IIIC non-small-cell lung cancer to radical surgery via anti-PD-1 immunotherapy combined with chemotherapy and anti-angiogenesis: A case report and literature review
Guohua Jia, Shuimei Zhou, Tangpeng Xu, Yabing Huang, Xiangpan Li
Frontiers in Oncology.2022;[Epub] CrossRef
A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation‐positive non‐small cell lung cancer (stage III) who have not progressed following definitive, platinum‐based, chemoradiatio
Juwhan Choi, Jeong Eun Lee, Chang‐Min Choi, In‐Jae Oh, Kye Young Lee, Tae Won Jang, Seung Hyeun Lee, Eun Young Kim, Dong Won Park, Sun Hyo Park, Sung Yong Lee
Thoracic Cancer.2022; 13(23): 3431. CrossRef
Prognostic Value of Combing Primary Tumor and Nodal Glycolytic–Volumetric Parameters of 18F-FDG PET in Patients with Non-Small Cell Lung Cancer and Regional Lymph Node Metastasis
Yu-Hung Chen, Sung-Chao Chu, Ling-Yi Wang, Tso-Fu Wang, Kun-Han Lue, Chih-Bin Lin, Bee-Song Chang, Dai-Wei Liu, Shu-Hsin Liu, Sheng-Chieh Chan
Diagnostics.2021; 11(6): 1065. CrossRef

12,403 View
251 Download
20 Web of Science
20 Crossref

Gynecologic cancer

Nationwide Comparison of Surgical and Oncologic Outcomes in Endometrial Cancer Patients Undergoing Robotic, Laparoscopic, and Open Surgery: A Population-Based Cohort Study: Kyung-Jin Eoh, Eun-Ji Nam, Sang-Wun Kim, Minkyung Shin, Stella J-H Kim, Jung-Ae Kim, Yong-Tae Kim; Cancer Res Treat. 2021;53(2):549-557. Published online October 22, 2020; DOI: https://doi.org/10.4143/crt.2020.802

Abstract PDF Supplementary Material PubReader ePub

Purpose
Population-based comparisons between minimally invasive surgery (MIS) (robotic surgery [RS] and laparoscopic surgery [LS]) and open surgery (OS) for managing endometrial cancer are lacking. This study aimed to compare surgical and oncologic outcomes between endometrial cancer patients who underwent surgical staging via MIS or OS.
Materials and Methods
A population-based retrospective cohort study was performed using claims data from the Korean National Health Insurance database from January 2012 to December 2016. All patients who underwent hysterectomy under diagnosis of endometrial cancer were identified. Patients were classified into RS, LS, and OS groups. Operative and oncologic outcomes were compared among the three groups after adjustments for age group, risk group (adjuvant therapy status), modified Charlson comorbidity index, income level, insurance type, and index year using propensity scores obtained via the inverse probability of treatment weighted method.
Results
After adjustment, 5,065 patients (RS, n=315; LS, n=3,248; OS, n=1,503) were analyzed. Patient demographics were comparable. Hospital stay, postoperative complications, and cost were more favorable in the RS and LS groups than in the OS group (all p < 0.001). Five-year overall survival was significantly longer in the RS and LS groups than in the OS group (94.8%, 91.9%, and 86.9%, respectively; p < 0.001). Moreover, the survival benefit of RS was shown in the subgroup analysis of low-risk endometrial cancer patients.
Conclusion
Our study provides further evidence for the RS being a safe surgical alternative to the LS and OS, especially in low-risk endometrial cancer patients, offering surgical and oncologic outcomes equivalent to other surgical approaches.

Citations

Citations to this article as recorded by

Clinical effectiveness of laparoscopic versus open surgery for apparently early-stage endometrial cancer: Application of a treatment effect model
Chuenkamon Charakorn, Sasivimol Rattanasiri, Arb-aroon Lertkhachonsuk, Panida Mathaveechotikul, Gareth J McKay, John Attia, Ammarin Thakkinstian
Journal of Gynecologic Oncology.2027;[Epub] CrossRef
Comparison of Laparotomy and Laparoscopy for the Management of Endometrioid Endometrial Cancer with Cervical Involvement
Cem Yagmur Ozdemir, Nayif Cicekli, Hüseyin Coşkun, Riza Dur, Ilhan Demir, Necat Çağatay Sezer, Dagistan Tolga Arioz
The Journal of Obstetrics and Gynecology of India.2026; 76(2): 113. CrossRef
Robotic Surgery in Gynecology: Balancing Clinical Benefit, Cost-Effectiveness, and Accessibility
Dario Colacurci, Giuseppe Bifulco, Mario Ascione, Ina Shehaj, Morva Tahmasbi Rad, Khayal Gasimli, Sven Becker
Journal of Clinical Medicine.2026; 15(10): 3628. CrossRef
Robotic-assisted surgery versus conventional laparoscopy in endometrial cancer: a systematic review and meta-analysis
Noémi Kalas, Balázs Lintner, Barbara Sebők, Balázs Vida, Lotti Lőczi, Petra Merkely, Ferenc Bánhidy, Nándor Ács, Richárd Tóth, Márton Keszthelyi
European Journal of Surgical Oncology.2026; 52(8): 111861. CrossRef
Robot-assisted versus conventional laparoscopic surgery for endometrial cancer: an updated systematic review and meta-analysis
Kanwal Majeed, Muhammad Ahmed, Hassam Ali, Aamna Kashif, Muzna Murtaza, Zainab Muhammad Hanif, Fnu Sidra, Atiya Batool, Jones Onesime, Aymar Akilimali
BMC Surgery.2026;[Epub] CrossRef
Surgical staging in early endometrial cancer without intra-uterine manipulator using the da Vinci SP robotic system
Eun Bi Jang, Yong-hee Park, Kyeong A So, Sun Joo Lee, Tae Jin Kim, Seung-Hyuk Shim
International Journal of Gynecological Cancer.2025; 35(2): 101615. CrossRef
Comparing robotic, laparoscopic, and laparotomy in endometrial cancer: a network meta-analysis
Wen-Rui Huang, Xing-Yan Ou, Xing-Zi Fang, Xiao-Xuan Tang, Lei Chen, Jing Ling, Wen-Cong Song, Xue-Lian Du
International Journal of Surgery.2025; 111(2): 2208. CrossRef
Robotic-assisted versus laparoscopic surgery for colorectal cancer in high-risk patients: a systematic review and meta-analysis
S. Gahunia, J. Wyatt, S. G. Powell, S. Mahdi, S. Ahmed, K. Altaf
Techniques in Coloproctology.2025;[Epub] CrossRef
Minimally Invasive Surgery in Endometrial Cancer: Superior for Low-Risk and Comparable for High-Risk Cases in a 20-Year Cohort Study
Valentina Auletta, Maya Ehab Hassan, Angela Kather, Nikolaus Gaßler, Davit Bokhua, Ingo B. Runnebaum
Geburtshilfe und Frauenheilkunde.2025; 85(07): 724. CrossRef
Adoption and implementation of robotic surgery in Türkiye: a multi-level qualitative analysis of individual, institutional, and systemic dynamics
Hilal Demirhan Keles, Erdal Eke
Journal of Robotic Surgery.2025;[Epub] CrossRef
Costs and cost-effectiveness of robotic-assisted surgery in South Korea: a systematic review and meta-analysis
Young Eun Hong, Hana Shim, Minkyung Shin
Frontiers in Public Health.2025;[Epub] CrossRef
Impact of Minimally Invasive Surgery on Quality of Life and Infertility in Deep Infiltrating Endometriosis
Andrei Manu, Elena Poenaru, Florentina Duica, Smaranda Stoleru, Alexandra Irma Gabriela Bausic, Bogdan-Catalin Coroleuca, Ciprian-Andrei Coroleuca, Cristina Iacob, Elvira Brătilă
Journal of Clinical Medicine.2025; 14(20): 7256. CrossRef
Real-world outcomes of robotic and non-robotic hysterectomy for endometrial cancer: insights from a national cohort
Hui-Hsuan Lau, Yu-san Chien, Jiun-Yi Li, Ching-Hu Chung
Journal of Robotic Surgery.2025;[Epub] CrossRef
Robot-assisted pelvic and renal surgery compared with laparoscopic or open surgery: Literature review of cost-effectiveness and clinical outcomes
Thomas Davidson, Rune Sjödahl, Åke Aldman, Claes Lennmarken, Ann-Sofi Kammerlind, Elvar Theodorsson
Scandinavian Journal of Surgery.2024; 113(1): 13. CrossRef
Progress of Research on the Application of Robotic Surgical System in Gynecologic Malignancies
璐余
Advances in Clinical Medicine.2024; 14(03): 327. CrossRef
Sociodemographic, clinical characteristics, and treatment patterns of endometrial cancer cases in Puerto Rico during the period 2009 to 2015: A retrospective study
Yisel Pagán Santana, Maira Castañeda Ávila, Ruth Ríos Motta, Karen J. Ortiz Ortiz, Asmerom Tesfamariam Sengal
PLOS ONE.2024; 19(5): e0302253. CrossRef
Comparison of Long-Term Outcomes in Early-Stage Endometrial Cancer: Robotic Single-Site vs. Multiport Laparoscopic Surgery
Heeju Kang, Hyewon Chung, Seungmee Lee, Tae-Kyu Jang, So-Jin Shin, Sang-Hoon Kwon, Chi-Heum Cho
Journal of Personalized Medicine.2024; 14(6): 601. CrossRef
Impact of Robotic Assistance on Minimally Invasive Surgery for Type II Endometrial Cancer: A National Cancer Database Analysis
Kelly Lamiman, Michael Silver, Nicole Goncalves, Michael Kim, Ioannis Alagkiozidis
Cancers.2024; 16(14): 2584. CrossRef
The problem of pharmacological correction of affective status disorders and decreased quality of life in oncogynecological diseases (literature review)
А. P. Alekseeva
Continuing Medical Education and Science.2024; 19(1): 7. CrossRef
Clinical Relevance of Uterine Manipulation on Oncologic Outcome in Robot-Assisted versus Open Surgery in the Management of Endometrial Cancer
Kyung Jin Eoh, Yoo-Na Kim, Eun Ji Nam, Sang Wun Kim, Young Tae Kim
Journal of Clinical Medicine.2023; 12(5): 1950. CrossRef
Trend and characteristics of minimally invasive surgery for patients with endometrial cancer in Japan
Hiroshi Yoshida, Hiroko Machida, Koji Matsuo, Yoshito Terai, Takuma Fujii, Masaki Mandai, Kei Kawana, Hiroaki Kobayashi, Mikio Mikami, Satoru Nagase
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Clinical Relevance of Red Blood Cell Distribution Width (RDW) in Endometrial Cancer: A Retrospective Single-Center Experience from Korea
Kyung-Jin Eoh, Tae-Kyung Lee, Eun-Ji Nam, Sang-Wun Kim, Young-Tae Kim
Cancers.2023; 15(15): 3984. CrossRef
Robot-Assisted Surgery in the Treatment of Gynecological Carcinoma and Malignancies: Introduction to the da Vinci Robotic Surgery System
Arnav Goel, Soumya Pamnani, Ashish Anjankar
Cureus.2023;[Epub] CrossRef
Robot-assisted versus conventional laparoscopic surgery for endometrial cancer: long-term comparison of outcomes
Kyung Jin Eoh, Tae-Joong Kim, Jeong-Yeol Park, Hee Seung Kim, Jiheum Paek, Young Tae Kim
Frontiers in Oncology.2023;[Epub] CrossRef
Comparison of Single-Port Laparoscopy with Other Surgical Approaches in Endometrial Cancer Surgical Staging: Propensity-Score-Matched Analysis
Sang Hyun Cho, Jung-Yun Lee, Eun Ji Nam, Sunghoon Kim, Young Tae Kim, Sang Wun Kim
Cancers.2023; 15(22): 5322. CrossRef
Short-Term Outcome of Robotic versus Laparoscopic Hysterectomy for Endometrial Cancer in Women with Diabetes: Analysis of the US Nationwide Inpatient Sample
Huang-Pin Shen, Chih-Jen Tseng
Journal of Clinical Medicine.2023; 12(24): 7713. CrossRef
Laparoscopic vs. open procedure for intermediate‑ and high‑risk endometrial cancer: a minimum 4-year follow-up analysis
Xing Zhou, Sitian Wei, Qingchun Shao, Jun Zhang, Rong Zhao, Rui Shi, Wei Zhang, Kejun Dong, Wan Shu, Hongbo Wang
BMC Cancer.2022;[Epub] CrossRef
Oncologic safety of laparoscopic surgery for women with apparent early‐stage uterine serous carcinoma: A multi‐institutional retrospective cohort study
Yu Xu, Juan Shen, Qianwen Zhang, Yuedong He, Cheng Chen, Yong Tian
International Journal of Gynecology & Obstetrics.2022; 158(1): 162. CrossRef
Impact of lymphadenectomy on short- and long-term complications in patients with endometrial cancer
Louisa Proppe, Ibrahim Alkatout, Ricarda Koch, Sascha Baum, Christos Kotanidis, Achim Rody, Lars C. Hanker, Georgios Gitas
Archives of Gynecology and Obstetrics.2022; 306(3): 811. CrossRef
Survival Analysis in Endometrial Carcinomas by Type of Surgical Approach: A Matched-Pair Study
Pluvio J. Coronado, Agnieszka Rychlik, Laura Baquedano, Virginia García-Pineda, Maria A. Martínez-Maestre, Denis Querleu, Ignacio Zapardiel
Cancers.2022; 14(4): 1081. CrossRef
Robot-assisted versus laparoscopic minimally invasive surgery for the treatment of stage I endometrial cancer
Peter A. Argenta, Jordan Mattson, Colleen L. Rivard, Elizabeth Luther, Alexandra Schefter, Rachel I. Vogel
Gynecologic Oncology.2022; 165(2): 347. CrossRef
Effects of Quantitative Nursing Combined with Psychological Intervention in Operating Room on Stress Response, Psychological State, and Prognosis of Patients Undergoing Laparoscopic Endometrial Cancer Surgery
Xiaojing Chen, Huiyan Li, Shouyan Wang, Yu Wang, Li Zhang, Dandan Yao, Li Li, Ge Gao, Shakeel Ahmad
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Increased HSF1 Promotes Infiltration and Metastasis in Cervical Cancer via Enhancing MTDH-VEGF-C Expression
Xueyan Shi, Zhenghao Deng, Shouman Wang, Shuai Zhao, Lan Xiao, Jiang Zou, Tao Li, Sichuang Tan, SipAin Tan, Xianzhong Xiao
OncoTargets and Therapy.2021; Volume 14: 1305. CrossRef
Surgical and Patient Outcomes of Robotic Versus Conventional Laparoscopic Hysterectomy: A Systematic Review
Khadija Alshowaikh, Katarzyna Karpinska-Leydier, Jashvini Amirthalingam , Gokul Paidi, Anuruddhika I Iroshani Jayarathna, Divya Bala Anthony Manisha R Salibindla, Huseyin Ekin Ergin
Cureus.2021;[Epub] CrossRef
Surgical outcomes of robotic-assisted surgery in endometrial cancer:comparison with laparoscopic surgery and laparotomy
Yoshitsugu Chigusa, Sae Yu, Naoki Horikawa, Haruko Okamoto, Masumi Sunada, Ukita Masayo, Koji Yamanoi, Ken Yamaguchi, Akihito Horie, Masaki Mandai
JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY.2021; 37(2): 10. CrossRef

10,721 View
246 Download
33 Web of Science
35 Crossref

Gastrointestinal cancer

Tumor Control and Overall Survival after Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer: A Meta-Analysis: Hoon Sik Choi, Bae Kwon Jeong, Ki Mun Kang, Hojin Jeong, Jin Ho Song, In Bong Ha, Oh-Young Kwon; Cancer Res Treat. 2020;52(4):1188-1198. Published online July 21, 2020; DOI: https://doi.org/10.4143/crt.2020.402

Abstract PDF Supplementary Material PubReader ePub

Purpose
In pulmonary oligometastases from colorectal cancer (POM-CRC), the primarily recommended local therapy is metastasectomy. Stereotactic body radiotherapy (SBRT) is another local therapy modality that is considered as an alternative option in patients who cannot undergo surgery. The purpose of this meta-analysis is to demonstrate the effects of SBRT on POM-CRC by integrating the relevant studies.
Materials and Methods
The authors explored MEDLINE, EMBASE, Cochrane Library, Web of Science, and SCOPUS, and selected studies including patients treated with SBRT for POM-CRC and availability of local control (LC) or overall survival (OS) rate. In this meta-analysis, the effect of SBRT was presented in the form of the LC and OS rates for 1, 2, 3, and 5 years after SBRT as pooled estimates, and the frequency of pulmonary toxicity of grade 3 or higher after SBRT (PTG3-SBRT).
Results
Fourteen full texts among the searched 4,984 studies were the objects of this meta-analysis. The overall number of POM-CRC patients was 495 as per the integration of 14 studies. The pooled estimate LC rate at 1, 2, 3, and 5 years after SBRT was 81.0%, 71.5%, 56.0%, and 61.8%, and the OS rate was 86.9%, 70.1%, 57.9%, and 43.0%, respectively. The LC and OS rates gradually declined until 3 years after SBRT in a similar pattern. Among the 14 studies, only two studies reported PTG3-SBRT as 2.2% and 10.8%, respectively.
Conclusion
For POM-CRC, SBRT is an ablative therapy with a benefit on LC and OS rates and less adverse effects on the lung.

Citations

Citations to this article as recorded by

Therapeutic approaches to pulmonary metastases in colorectal cancer
I. Yu. Kokhanovskaia, A. S. Fatyanova, E. A. Tarabrin, I. V. Reshetov
Research and Practical Medicine Journal.2025; 12(3): 61. CrossRef
Treatment of Colorectal Lung Metastases: Two Centers Retrospective Study
Myrtle F. Krul, Jan M. van Rees, Amihan M. de Boer, Karlijn K. Neve, Cornelis Verhoef, Koert F.D. Kuhlmann, Tarik R. Baetens, Tineke E. Buffart, Joost L. Knegjens, Houke M. Klomp, Theo J.M. Ruers, Marianne de Vries, Joost Rothbarth, Esther van Meerten, Jo
Digestive Diseases.2024; 42(6): 538. CrossRef
Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study
Emmanuel Mesny, Myriam Ayadi, Pauline Dupuis, Guillaume Beldjoudi, Ronan Tanguy, Isabelle Martel-Lafay
Radiation Oncology.2023;[Epub] CrossRef
Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
Davide Franceschini, Maria Ausilia Teriaca, Luca Dominici, Ciro Franzese, Marta Scorsetti
Cancer Management and Research.2021; Volume 13: 7009. CrossRef

11,735 View
172 Download
14 Web of Science
4 Crossref

Laparoscopic Surgery for Colorectal Cancer in Korea: Nationwide Data from 2013 to 2018: Sun Jin Park, Kil Yeon Lee, Suk-Hwan Lee; Cancer Res Treat. 2020;52(3):938-944. Published online April 6, 2020; DOI: https://doi.org/10.4143/crt.2020.043

Abstract PDF PubReader ePub

Purpose
We report nationwide data on the current status of laparoscopic surgery for colorectal cancer (CRC) in Korea.
Materials and Methods
Nationwide data of patients who underwent surgery for CRC from 2013 to 2018 were obtained from the Health Insurance Review & Assessment Service database. Data and trends of laparoscopy use for colorectal resection over six years were examined.
Results
In Korea, a total of 117,320 patients underwent surgical resection for CRC from 2013 to 2018. The proportion of laparoscopic resection increased from 64.9% in 2013 to 78.5% in 2018. The rate of laparoscopic resection for colon cancer increased from 64.7% in 2013 to 77.4% in 2018. For rectal cancer, the rate of laparoscopic resection increased from 65.4% to 81.6%. Males accounted for 59.8% of all patients, but females surpassed males at over 80 years of age. The age of peak incidence was in the 60s for males and in the 70s for females. A steady increase in the number of patients undergoing surgery for CRC was observed over 80 years of age.
Conclusion
The laparoscopic penetration rate for CRC in Korea continued to increase annually and reached 78.5% in 2018.

Citations

Citations to this article as recorded by

Short-Term Outcomes of Laparoscopic Colorectal Cancer Surgery at a Tertiary Care Hospital: A Single-Surgeon Experience
Hamza Çınar, Yasir Keçelioğlu
Middle Black Sea Journal of Health Science.2026; 12(1): 105. CrossRef
Comparison of minimally invasive versus open pancreaticoduodenectomy in patients with obesity, a NSQIP analysis
Natalie Gugala, Sukhdeep Jatana, Kevin Verhoeff, A. M. James Shapiro, David L. Bigam, Blaire Anderson, Khaled Dajani
Clinical Surgical Oncology.2026; 5(2): 100129. CrossRef
Cost-effectiveness and readmission rates of laparoscopic vs. open surgery for colorectal cancer: evidence from the health insurance review and assessment service dataset in South Korea
Sanghyun An, Sung Eun Hong, Moo Hyun Kim, Ik Yong Kim
Frontiers in Surgery.2025;[Epub] CrossRef
Laparoscopic and robotic surgery for colorectal cancer in Korea: a nationwide health insurance database analysis from 2019 to 2023
Eun Ji Park, Hyun Gu Lee, Youn Young Park, Sun Jin Park, Kil Yeon Lee, Suk-Hwan Lee
Journal of Minimally Invasive Surgery.2025; 28(1): 25. CrossRef
Label‐Free Typing of Colorectal Cancer by Optical Time‐Stretch Imaging Flow Cytometry With Multi‐Instance Learning
Sini Pi, Liye Mei, Liang Tao, Sisi Mei, Zhaoyi Ye
Journal of Biophotonics.2025;[Epub] CrossRef
Efficacy of laparoscopic radical resection of colorectal cancer in older patients and its effects on inflammatory factors
Zhen-Yu Min, Jie Zhou, Zhong-Wei Zhu, Zhen-Zhong Fa
World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Learning curve for single-port robot-assisted colectomy
Moon Suk Choi, Seong Hyeon Yun, Sung Chul Lee, Jung Kyong Shin, Yoon Ah Park, Jungwook Huh, Yong Beom Cho, Hee Cheol Kim, Woo Yong Lee
Annals of Coloproctology.2024; 40(1): 44. CrossRef
Clinical effect of laparoscopic radical resection of colorectal cancer based on propensity score matching
Yang Liu, Xian-Xue Wang, Yu-Lin Li, Wen-Tao He, Hong Li, Hua Chen
World Journal of Gastrointestinal Surgery.2024; 16(1): 124. CrossRef
The impact of surgical volume on outcomes in newly diagnosed colorectal cancer patients receiving definitive surgeries
Chiu-Mei Yeh, Tzu-Yu Lai, Yu-Wen Hu, Chung-Jen Teng, Nicole Huang, Chia-Jen Liu
Scientific Reports.2024;[Epub] CrossRef
Essential knowledge and technical tips for total mesorectal excision and related procedures for rectal cancer
Min Soo Cho, Hyeon Woo Bae, Nam Kyu Kim
Annals of Coloproctology.2024; 40(4): 384. CrossRef
Robotic surgery may lead to reduced postoperative inflammatory stress in colon cancer: a propensity score–matched analysis
Eun Ji Park, Gyong Tae Noh, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Byung Soh Min
Annals of Coloproctology.2024; 40(6): 594. CrossRef
Incidence of incisional hernia after major colorectal cancer surgery & analysis of associated risk factors in Asian population: Is laparoscopy any better?
Shao Nan Khor, S.H.X. Cheok, Rehena Sultana, Emile Kwong Wei Tan
Asian Journal of Surgery.2023; 46(1): 99. CrossRef
Intracorporeal anastomosis for minimally invasive right colectomy – is it time for wider uptake?
Kim‐Chi Phan‐Thien, Edward A. Cooper, David Z. Lubowski
ANZ Journal of Surgery.2023; 93(3): 454. CrossRef
Laparoscopic versus open surgery for colonoscopic perforation: A systematic review and meta-analysis
Wu Zhong, Chuanyuan Liu, Chuanfa Fang, Lei Zhang, Xianping He, Weiquan Zhu, Xueyun Guan
Medicine.2023; 102(24): e34057. CrossRef
Results of Laparoscopic Surgery and D3 Lymph Node Dissection Combined With Chemotherapy for the Radical Treatment of Advanced-Stage Right Colon Cancer: A Single-Center Observational Study in Vietnam
Long Huynh Thanh, Khiem Nguyen Manh, Minh Nguyen Thi, Anh Nguyen Tri Trung, Kien Nguyen Trung, Thang Le Viet, Nung Vu Huy
Cureus.2023;[Epub] CrossRef
Learning curve of single-incision laparoscopic totally extraperitoneal repair (SILTEP) for inguinal hernia
Y. Y. Park, K. Lee, S. T. Oh, J. Lee
Hernia.2022; 26(3): 959. CrossRef
Laparoscopic Radical Resection of Colorectal Cancer in the Treatment of Elderly Colorectal Cancer and Its Effect on Gastrointestinal Function
Biao Liu, Chuanhui Yao, Haiying Li
Frontiers in Surgery.2022;[Epub] CrossRef
Learning curve for single-port robot-assisted rectal cancer surgery
Moon Suk Choi, Seong Hyeon Yun, Chang Kyu Oh, Jung Kyong Shin, Yoon Ah Park, Jung Wook Huh, Yong Beom Cho, Hee Cheol Kim, Woo Yong Lee
Annals of Surgical Treatment and Research.2022; 102(3): 159. CrossRef
Comparison of clinical efficacy and postoperative inflammatory response between laparoscopic and open radical resection of colorectal cancer
Long-Hai He, Bo Yang, Xiao-Qin Su, Yue Zhou, Zhen Zhang
World Journal of Clinical Cases.2022; 10(13): 4042. CrossRef
Risk factors and economic burden of postoperative anastomotic leakage related events in patients who underwent surgeries for colorectal cancer
Jeonghyun Kang, Hyesung Kim, HyeJin Park, Bora Lee, Kang Young Lee, Alberto Meyer
PLOS ONE.2022; 17(5): e0267950. CrossRef
Minimally Invasive Pancreatoduodenectomy: Contemporary Practice, Evidence, and Knowledge Gaps
Jacob Ghotbi, Mushegh Sahakyan, Kjetil Søreide, Åsmund Avdem Fretland, Bård Røsok, Tore Tholfsen, Anne Waage, Bjørn Edwin, Knut Jørgen Labori, Sheraz Yaqub, Dyre Kleive
Oncology and Therapy.2022; 10(2): 301. CrossRef
A retrospective study of post-operative complications and cost analysis in robotic rectal resection versus laparoscopic rectal resection
Muhammad Ali, Xiaodong Zhu, Yang Wang, Jianyue Ding, Qi Zhang, Qiannan Sun, Shantanu Baral, Daorong Wang
Frontiers in Surgery.2022;[Epub] CrossRef
Multidisciplinary treatment strategy for early colon cancer
Gyung Mo Son, Su Bum Park, Tae Un Kim, Byung-Soo Park, In Young Lee, Joo-Young Na, Dong Hoon Shin, Sang Bo Oh, Sung Hwan Cho, Hyun Sung Kim, Hyung Wook Kim
Journal of the Korean Medical Association.2022; 65(9): 558. CrossRef
Epidemiology, risk factors, and prevention of colorectal cancer
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
Journal of the Korean Medical Association.2022; 65(9): 549. CrossRef
Multidisciplinary Treatment Strategy for Early Colon Cancer: A Review-An English Version
Gyung Mo Son, Su Bum Park, Tae Un Kim, Byung-Soo Park, In Young Lee, Joo-Young Na, Dong Hoon Shin, Sang Bo Oh, Sung Hwan Cho, Hyun Sung Kim, Hyung Wook Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 203. CrossRef
Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
Journal of the Anus, Rectum and Colon.2022; 6(4): 231. CrossRef
Postoperative complications observed with robotic versus laparoscopic surgery for the treatment of rectal cancer
Chengkui Liu, Xiaoqing Li, Qingfeng Wang
Medicine.2021; 100(36): e27158. CrossRef
Is Laparoscopic Complete Mesocolic Excision and Central Vascular Ligation Really Necessary for All Patients With Right-Sided Colon Cancer?
Gyung Mo Son, In Young Lee, Yoon Suk Lee, Bong-Hyeon Kye, Hyeon-Min Cho, Je-Ho Jang, Chang-Nam Kim, Kil Yeon Lee, Suk-Hwan Lee, Jun-Gi Kim
Annals of Coloproctology.2021; 37(6): 434. CrossRef
Preoperative Colonoscopic Tattooing Using a Direct Injection Method with Indocyanine Green for Localization of Colorectal Tumors: An Efficacy and Safety Comparison Study
Young Jin Kim, Ji Won Park, Han-Ki Lim, Yoon-Hye Kwon, Min Jung Kim, Eun Kyung Choe, Sang Hui Moon, Seung-Bum Ryoo, Seung-Yong Jeong, Kyu Joo Park
The Journal of Minimally Invasive Surgery.2020; 23(4): 186. CrossRef

11,087 View
189 Download
28 Web of Science
29 Crossref

Displacement of Surgical Clips in Patients with Human Acellular Dermal Matrix in the Excision Cavity during Whole Breast Irradiation Following Breast-Conserving Surgery: Wonguen Jung, Kyubo Kim, Nam Sun Paik; Cancer Res Treat. 2020;52(2):388-395. Published online August 13, 2019; DOI: https://doi.org/10.4143/crt.2019.213

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the displacement of surgical clips in the excision cavity during whole breast irradiation following breast-conserving surgery (BCS) with or without acellular dermal matrix (ADM) insertion, and to analyze clinicopathologic factors associated with the displacement of surgical clips.
Materials and Methods
From 2016 to 2017, 100 consecutive breast cancer patients who underwent BCS with the placement of surgical clips (superior, inferior, medial, lateral, and deep sides) in the tumor bed were included in this study. All patients took first planning computed tomography (CT) scan (CT 1) before whole breast irradiation and second CT scan (CT 2) before boost irradiation. Between two sets of planning CT, the displacement of surgical clips was calculated from the ΔX (lateral–medial), ΔY (anterior–posterior), ΔZ (superior–inferior), and three-dimensional (3D) directions. Patients were divided into two groups according to the breast volume replacement with ADM: group A with ADM and group B without ADM.
Results
The means and 1 standard deviations of 3D displacement for superior, inferior, medial, lateral and deep clips were 5.2±2.9, 5.2±3.2, 5.6±4.5, 5.6±4.3, and 4.9±4.9 mm in entire cohort (n=100); 5.6±2.6, 6.0±3.5, 6.7±5.8, 6.7±5.7, and 6.1±7.4 mm in group A (n=38); 4.9±3.1, 4.8±3.0, 5.0±3.5, 5.0±2.9, and 4.3±2.8 mm in group B (n=62), respectively. The 3D displacements of group A were longer than those of group B, but only significant difference was observed in lateral clip (p=0.047).
Conclusion
This study demonstrated displacement of surgical clips during whole breast irradiation in patients with ADM insertion. For patients who had breast volume replacement using ADM, adaptive boost planning should be considered.

Citations

Citations to this article as recorded by

Automatic segmentation of target volume of breast radiotherapy on CT using MSR-UNet: A multicenter study
Desheng Zheng, Jianshu Wang, Jiping Liu, Hangyu Yuan, Jingshuo Xue, Hai Zeng, Weijia Zhang, Xiaoyu Li, Jun Cai, Xuwei Tian
Applied Radiation and Isotopes.2026; 233: 112635. CrossRef
Interobserver variability of clinical target volume delineation in patients undergoing breast-conserving surgery without surgical clips: a pilot study on preoperative magnetic resonance simulation
Shuning Jiao, Yiqing Wang, Jiabin Ma, Jing Shen, Xi-Qian Zhang, Bing Zhou, Xiansong Sun, Haoran Xu, Xia Liu, Ke Hu, Fuquan Zhang, Xiaorong Hou, Jie Qiu
BMC Cancer.2024;[Epub] CrossRef
What Should We Know in Postoperative Surveillance Imaging After Oncoplastic Breast-Conserving Surgery with Pellet-Type Acellular Dermal Matrix?
Yeong Yi An, Hyejung Hwang, Young Jin Suh
Academic Radiology.2023; 30: S16. CrossRef
Imaging surveillance for the detection of ipsilateral local tumor recurrence in patients who underwent oncoplastic breast-conserving surgery with acellular dermal matrix: abbreviated MRI versus conventional mammography and ultrasonography
Mi Young Kim, Young Jin Suh, Yeong Yi An
World Journal of Surgical Oncology.2021;[Epub] CrossRef

8,078 View
178 Download
4 Web of Science
4 Crossref

SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer: Yoo-Kang Kwak, Hee Hyun Park, Kyu Hye Choi, Eun Young Park, Soo Yoon Sung, Sea-Won Lee, Ji Hyun Hong, Hyo Chun Lee, Ie Ryung Yoo, Yeon Sil Kim; Cancer Res Treat. 2020;52(1):85-97. Published online May 17, 2019; DOI: https://doi.org/10.4143/crt.2019.007

Abstract PDF PubReader ePub

Purpose
Fluorodeoxyglucose positron emission tomography–computed tomography (PET-CT) is gaining evidence as a predictive factor in non-small cell lung cancer (NSCLC). Stereotactic ablative radiotherapy (SABR) is the standard treatment in early-stage NSCLC when a patient is unsuitable for surgery. We performed a study to assess the prognostic clinical significance of PET-CT after SABR in early-stage NSCLC.
Materials and Methods
Seventy-six patients with stage I NSCLC treated with SABR were investigated. Total radiation dose ranged from 36 to 63 Gy in three to eight fractions depending on tumor location and size. Respiratory motion control was implemented at simulation and during treatment. PET-CT prior to SABR was performed in 66 patients (86.8%).
Results
Median follow-up time was 32 months (range, 5 to 142 months). Local control rate at 1, 2, and 5 years were 95.9%, 92.8%, and 86.7%, respectively. Overall survival (OS) at 1, 2, and 5 years were 91.0%, 71.3%, and 52.1% respectively. Cause-specific survival at 1, 2, and 5 years were 98.6%, 93.1%, and 84.3% respectively. Tumor size and pre-SABR maximal standardized uptake value (SUVmax) demonstrated statistical significance in the Kaplan-Meier survival analyses with log-rank test. In multivariate analyses pre-SABR SUVmax remained statistically significant in correlation to OS (p=0.024; hazard ratio [HR], 3.2; 95% confidence interval [CI], 1.2 to 8.8) and with marginal significance in regards to regional progression-free survival (p=0.059; HR, 32.5; 95% CI, 2.6 to 402.5).
Conclusion
Pre-SABR SUVmax demonstrated a predictive power in statistical analyses. Tumors with SUVmax above 6 at diagnosis were associated with inferior outcomes.

Citations

Citations to this article as recorded by

Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer
Yupeng Di, Haifeng Pang, Xuan Wang, Lingling Meng
Clinical Lung Cancer.2026; 27(6): 75. CrossRef
Enhanced NSCLC subtyping and staging through attention-augmented multi-task deep learning: A novel diagnostic tool
Runhuang Yang, Weiming Li, Siqi Yu, Zhiyuan Wu, Haiping Zhang, Xiangtong Liu, Lixin Tao, Xia Li, Jian Huang, Xiuhua Guo
International Journal of Medical Informatics.2025; 193: 105694. CrossRef
The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients
Maria Fala, Eleni Josephides, Sweni Shah, Hemal Ariyaratne, Anant Patel, Gary J. R. Cook, Sugama Chicklore, Thomas Wagner
European Journal of Nuclear Medicine and Molecular Imaging.2025; 53(1): 181. CrossRef
Quantitative Imaging Biomarkers in Lung Cancer: Current Trends and Future Directions
Joice Prodigios, Ronak Kundalia, Amanda Acevedo, Jean Bontemps, David Pfaehler, Md Mahfuz Al Hasan, Kyle B. See, Nupur Verma, Daniela Hochhegger, Alysson Roncally Silva Carvalho, Tan-Lucien Mohammed, Bruno Hochhegger
Seminars in Roentgenology.2025; 60(4): 439. CrossRef
Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer – Results from a Single Institution Study
Benjamin George, Atallah Baydoun, Samar Bhat, Lauryn Bailey, Theodore Arsenault, Yilun Sun, Yuxia Zhang, Yiran Zheng, Prashant Vempati, Tarun Podder, Tithi Biswas
Clinical Lung Cancer.2024; 25(4): e181. CrossRef
Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis
Yongming Wu, Wenpeng Song, Denian Wang, Junke Chang, Yan Wang, Jie Tian, Sicheng Zhou, Yingxian Dong, Jing Zhou, Jue Li, Ziyi Zhao, Guowei Che
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer
Pengfei Zhang, Wei Chen, Kewei Zhao, Xiaowen Qiu, Tao Li, Xingzhuang Zhu, Peng Sun, Chunsheng Wang, Yipeng Song
BMC Medical Imaging.2023;[Epub] CrossRef
Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors
Jixia Han, Qi Song, Feng Guo, Rui Du, Henghu Fang, Jingbo Kang, Zejun Lu
Nuclear Medicine Communications.2022; 43(6): 717. CrossRef
Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer
Yu-Sen Huang, Jenny Ling-Yu Chen, Hsin-Ming Chen, Li-Hao Yeh, Jin-Yuan Shih, Ruoh-Fang Yen, Yeun-Chung Chang
BMC Cancer.2021;[Epub] CrossRef
Potential role of functional imaging in predicting outcome for patients treated with carbon ion therapy: a review
Giulia Riva, Sara Imparato, Giovanni Savietto, Mattia Pecorilla, Alberto Iannalfi, Amelia Barcellini, Sara Ronchi, Maria Rosaria Fiore, Chiara Paganelli, Giulia Buizza, Mario Ciocca, Guido Baroni, Lorenzo Preda, Ester Orlandi
The British Journal of Radiology.2021;[Epub] CrossRef
Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy
Jin Meng, Emmanuel Deshayes, Li Zhang, Wei Shi, Xiaomeng Zhang, Xingxing Chen, Xin Mei, Jinli Ma, Yizhou Jiang, Jiong Wu, Zhimin Shao, Xiaoli Yu, Zhaozhi Yang, Xiaomao Guo
Molecular Therapy Oncolytics.2021; 23: 412. CrossRef
Parámetros cuantitativos de la PET/TC con 18F-FDG como factores pronósticos en el cáncer de pulmón localizado e inoperable
J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M. Moreno, A. Martínez, P. Jiménez, A. Cobo
Revista Española de Medicina Nuclear e Imagen Molecular.2020; 39(6): 353. CrossRef
18F-FDG PET/CT quantitative parameters as prognostic factors in localized and inoperable lung cancer
J.R. Infante, J. Cabrera, J.I. Rayo, C. Cruz, J. Serrano, M Moreno, A. Martínez, P. Jiménez, A. Cobo
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2020; 39(6): 353. CrossRef

10,173 View
135 Download
12 Web of Science
13 Crossref

Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases: Wei-Rong Chen, Jia-Peng Deng, Jun Wang, Jia-Yuan Sun, Zhen-Yu He, San-Gang Wu; Cancer Res Treat. 2019;51(4):1437-1448. Published online March 4, 2019; DOI: https://doi.org/10.4143/crt.2018.611

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the effect of 21-gene recurrence score (RS) on predicting prognosis and chemotherapy decision in node micrometastases (N1mi) breast invasive ductal carcinoma (IDC).
Methods
Patients with stage T1-2N1mi and estrogen receptor-positive IDC diagnosed between 2004 and 2015 were included. The associations of 21-gene RS with breast cancer-specific survival (BCSS), chemotherapy decision, and benefit of chemotherapy were analyzed.
Results
We identified 4,758 patients including 1,403 patients (29.5%) treated with adjuvant chemotherapy. In the traditional RS cutoffs, 2,831 (59.5%), 1,634 (34.3%), and 293 (6.2%) patients were in the low-, intermediate-, and high-risk RS groups, respectively. In 3,853 patients with human epidermal growth factor receptor-2 (HER2) status available, most patients were HER2-negative disease (98.3%). A higher RS was independently related to chemotherapy receipt, and 14.0%, 47.7%, and 77.8% of patients in the low-, intermediate-, and high-risk RS groups received chemotherapy, respectively. The multivariate analysis indicated that a higher RS was related to worse BCSS (p < 0.001). The 5-year BCSS rates were 99.3%, 97.4%, and 91.9% in patients with low-, intermediate-, and high-risk RS groups, respectively (p < 0.001). However, chemotherapy receipt did not correlate with better BCSS in low-, intermediate-, or high-risk RS groups. There were similar trends using Trial Assigning Individualized Options for Treatment RS cutoffs.
Conclusion
The 21-gene RS does predict outcome and impact on chemotherapy decision of N1mi breast IDC. Large cohort and long-term outcomes studies are needed to identify the effects of chemotherapy in N1mi patients by different 21-gene RS groups.

Citations

Citations to this article as recorded by

21-gene recurrence score predictive of the benefit of postoperative radiotherapy after breast-conserving surgery for elderly patients with T1N0 and luminal breast cancer
Run-Jie Wang, Hai-Ying Liu, Lin-Feng Guo, De Yu, San-Gang Wu
Breast Cancer.2024; 31(6): 1156. CrossRef
Evaluation of adjuvant therapy for T1-2N1miM0 breast cancer without further axillary lymph node dissection
Baiyu Li, Jianbo Liu, Guangyin Wu, Qingyao Zhu, Shundong Cang
Frontiers in Surgery.2023;[Epub] CrossRef
Effectiveness of post-mastectomy adjuvant chemotherapy for the treatment of patients with prognostic stage IB breast cancer: A SEER-based study
HongMei Wang, Yi Peng, Jianbin Wu, ZhuangWei Chen, HuaLe Zhang
Asian Journal of Surgery.2023; 46(9): 3634. CrossRef
Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers
Ming Luo, Fu Li, Ka Su, Huiming Yuan, Jian Zeng
Cancer Biology & Therapy.2020; 21(2): 108. CrossRef
Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer
Yahiya Y. Syed
Molecular Diagnosis & Therapy.2020; 24(5): 621. CrossRef

9,397 View
141 Download
5 Web of Science
5 Crossref

Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study: Jiahui Huang, Xiaosong Chen, Xiaochun Fei, Ou Huang, Jiayi Wu, Li Zhu, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen; Cancer Res Treat. 2019;51(4):1336-1346. Published online February 12, 2019; DOI: https://doi.org/10.4143/crt.2018.504

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the changes of tumor infiltrating lymphocytes (TILs) between core needle biopsy (CNB) and surgery removed sample (SRS) in early stage breast cancer patients and to identify the correlating factors and prognostic significance of TILs changes.
Materials and Methods
A retrospective study was carried out on 255 patients who received CNB and underwent surgical resection for invasive breast cancer. Stromal TILs levels of CNB and SRS were evaluated respectively. Tumors with ≥50% stromal TILs were defined as lymphocyte-predominant breast cancer (LPBC). Clinicopathological variables were analyzed to determine whether there were factors associated with TILs changes. Log-rank tests and Cox proportional hazards models were used to analyze the influences of TILs and TILs changes on survival.
Results
SRS-TILs (median, 10.0%) were significant higher than CNB-TILs (median, 5.0%; p<0.001). Younger age (<60 years, p=0.016) and long surgery time interval (STI, ≥4 days; p=0.003) were independent factors correlating with higher TILs changes. CNB-LPBC patients showed better breast cancer-free interval (BCFI, p=0.021) than CNB-non-LPBC (CNB-nLPBC) patients. Patients were categorized into four groups according to the LPBC change pattern from CNB to SRS: LPBC→LPBC, LPBC→nLPBC, nLPBC→LPBC, and nLPBC→nLPBC, with estimated 5-year BCFI 100%, 100%, 69.7%, and 86.0% (p=0.016). nLPBC→LPBC pattern was an independent prognostic factor of worse BCFI (hazard ratio, 2.19; 95% confidence interval, 1.06 to 4.53; p=0.035) compared with other patterns.
Conclusion
TILs were significantly higher in SRS than in CNB. Higher TILs changes were associated with younger age and long STI. Changing from nLPBC to LPBC after CNB indicated a worse BCFI, which needs further validation.

Citations

Citations to this article as recorded by

Prediction of lymphocyte‐predominant breast cancer using microRNA expression in cytology specimens
Azusa Kai, Koji Arihiro, Hideo Shigematsu, Yukari Ohue‐Uchihata, Momoko Nakamura, Ai Amioka, Shinsuke Sasada, Morihito Okada
Cancer Cytopathology.2026;[Epub] CrossRef
Human umbilical cord-derived mesenchymal stem cells improve thymus and spleen functions in d-galactose-induced aged mice
Jianwei Xu, Li Dong, Xiaofen Xie, Bill D. Geng, Junhou Lu, Yongxi Dong, Yang Hu, Can Liu, Yuanhu Mao, Guo Ge, Zhenkui Ren
Scientific Reports.2025;[Epub] CrossRef
A nomogram to predict the pathological complete response in patients with breast cancer based on the TILs-US score
Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Koji Arihiro, Morihito Okada
Japanese Journal of Clinical Oncology.2024; 54(9): 967. CrossRef
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Anne Monette, Sarah Warren, J Carl Barrett, Charlie Garnett-Benson, Kurt A Schalper, Janis M Taube, Brian Topp, Alexandra Snyder
Journal for ImmunoTherapy of Cancer.2024; 12(7): e009427. CrossRef
Diagnostic performance of TILs–US score and LPBC in biopsy specimens for predicting pathological complete response in patients with breast cancer
Hideo Shigematsu, Kayo Fukui, Akiko Kanou, Erika Yokoyama, Makiko Tanaka, Mutsumi Fujimoto, Kanako Suzuki, Haruka Ikejiri, Ai Amioka, Emiko Hiraoka, Shinsuke Sasada, Akiko Emi, Tetsuya Nakagiri, Koji Arihiro, Morihito Okada
International Journal of Clinical Oncology.2024; 29(12): 1860. CrossRef
Stromal grading predicts pathologic complete response and prognosis in triple-negative breast cancer
Sean M. Hacking, Yihong Wang
Virchows Archiv.2023; 483(6): 765. CrossRef
Whole slide image features predict pathologic complete response and poor clinical outcomes in triple-negative breast cancer
Sean M. Hacking, Julie Karam, Kamaljeet Singh, Ece D. Gamsiz Uzun, Arlen Brickman, Evgeny Yakirevich, Ross Taliano, Yihong Wang
Pathology - Research and Practice.2023; 246: 154476. CrossRef
Tumor infiltrating lymphocytes and radiological picture of the tumor
Karolina Frankowska, Michał Zarobkiewicz, Izabela Dąbrowska, Agnieszka Bojarska-Junak
Medical Oncology.2023;[Epub] CrossRef
Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma
Minna Mutka, Kristiina Joensuu, Marja Heiskala, Mine Eray, Päivi Heikkilä
Virchows Archiv.2023; 483(2): 215. CrossRef
Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
Yujie Lu, Yiwei Tong, Xiaochun Fei, Xiaosong Chen, Kunwei Shen
Cancer Medicine.2023; 12(15): 16264. CrossRef
Time interval between breast cancer diagnosis and surgery is associated with disease outcome
Siji Zhu, Shuai Li, Jiahui Huang, Xiaochun Fei, Kunwei Shen, Xiaosong Chen
Scientific Reports.2023;[Epub] CrossRef
Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer
Amalia H. Landén, Kian Chin, Anikó Kovács, Erik Holmberg, Eva Molnar, Axel Stenmark Tullberg, Fredrik Wärnberg, Per Karlsson
Acta Oncologica.2023; 62(12): 1862. CrossRef
Magnetic Resonance Imaging Features Associated with a High and Low Expression of Tumor-Infiltrating Lymphocytes: A Stratified Analysis According to Molecular Subtypes
Jiejie Zhou, Yi Jin, Haiwei Miao, Shanshan Lu, Xinmiao Liu, Yun He, Huiru Liu, Youfan Zhao, Yang Zhang, Yan-Lin Liu, Zhifang Pan, Jeon-Hor Chen, Meihao Wang, Min-Ying Su
Cancers.2023; 15(23): 5672. CrossRef
Histopathological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) as Predictive Biomarker for Hormone Receptors Status, Proliferative Activity and Clinical Outcome in Her-2 Positive Breast Cancer
Giuseppe Angelico, Giuseppe Broggi, Rosario Caltabiano, Angela Santoro, Saveria Spadola, Nicoletta D’Alessandris, Giulia Scaglione, Michele Valente, Damiano Arciuolo, Alejandro Martin Sanchez, Gianluca Franceschini, Riccardo Masetti, Antonino Mulè, Gian F
Applied Sciences.2021; 11(15): 6788. CrossRef
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Zuzana Kos, Elvire Roblin, Rim S. Kim, Stefan Michiels, Brandon D. Gallas, Weijie Chen, Koen K. van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O. Nielsen, Sunil S. Badve, W. Fraser Symmans, Christos Sotiriou, David L. Rimm
npj Breast Cancer.2020;[Epub] CrossRef
Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?
Alexandra Caziuc, Diana Schlanger, Giorgiana Amarinei, George Calin Dindelegan
Journal of Clinical Medicine.2019; 8(4): 545. CrossRef

10,375 View
218 Download
18 Web of Science
16 Crossref

The Feasibility of Spinal Stereotactic Radiosurgery for Spinal Metastasis with Epidural Cord Compression: Yi-Jun Kim, Jin Ho Kim, Kyubo Kim, Hak Jae Kim, Eui Kyu Chie, Kyung Hwan Shin, Hong-Gyun Wu, Il Han Kim; Cancer Res Treat. 2019;51(4):1324-1335. Published online January 29, 2019; DOI: https://doi.org/10.4143/crt.2018.653

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the effectiveness and safety of spinal stereotactic radiosurgery (SRS) in treating spinal metastasis with epidural spinal cord compression (ESCC).
Materials and Methods
During 2013-2016, 149 regions of spinal metastasis in 105 patients treated with singlefraction (12-24 Gy) spinal SRS were reviewed. Cord compression of Bilsky grade 2 (with visible cerebrospinal fluid [CSF]) or 3 (no visible CSF) was defined as ESCC. Local progression (LP) and vertebral compression fracture (VCF) rates after SRS were evaluated using multivariate competing-risk regression analysis.
Results
The 1-year cumulative incidences of LP for Bilsky grades 0 (n=80), 1 (n=39), 2 (n=21), and 3 (n=9) were 3.0%, 8.4%, 0%, and 24.9%, respectively. Bilsky grade 2 ESCC did not significantly increase the LP rate (no LP for grade 2). The 1-year cumulative incidences of VCF for Bilsky grades 0, 1, 2, and 3 were 6.6%, 5.2%, 17.1%, and 12.1%, respectively. ESCC may increase VCF risk (subhazard ratio [SHR] for grade 2, 5.368; p=0.035; SHR for grade 3, 2.215; p=0.460). Complete or partial pain response rates after SRS were 79%, 78%, 53%, and 63% for Bilsky grades 0, 1, 2, and 3, respectively (p=0.008). No neurotoxicity of grade ≥ 3 was observed.
Conclusion
Spinal SRS for spinal metastasis with Bilsky grade 2 ESCC did not increase the LP rate, was not associated with severe neurotoxicity, and showed moderate VCF and pain response rates. Bilsky grade 3 had a high LP rate.

Citations

Citations to this article as recorded by

Treatment Approach for Bilsky Grade 2 Metastatic Epidural Spinal Cord Compression Based on Radiation Therapy Failure Risk
Sehan Park, Dong-Ho Lee, Chang Ju Hwang, Gumin Jeong, Ji Uk Choi, Hyuk-Joon Sohn, San Kim, Yeon Joo Kim, Jae Hwan Cho
Global Spine Journal.2026; 16(2): 862. CrossRef
Multi-fraction stereotactic body radiotherapy for spinal metastases
Suchet Taori, Samuel Adida, Akshath Rajan, James C. Bayley, Pascal O. Zinn, John C. Flickinger, Roberta K. Sefcik, Peter C. Gerszten
Journal of Neuro-Oncology.2026;[Epub] CrossRef
Palliative stereotactic body radiotherapy for spinal and non-spinal bone metastases: combining tradition and innovation
Kei Ito, Naoki Nakamura
International Journal of Clinical Oncology.2025; 30(8): 1492. CrossRef
Time Is Spine: A Novel Radiology Reporting System for Optimizing Spine Oncology Decision-Making and Reducing Time to Treatment
Colbey W. Freeman, Raghav Mattay, Charles E. Kahn, Laurie Loevner, Anish A. Butala, Neil R. Malhotra, Alvand Hassankhani
American Journal of Neuroradiology.2025; 46(11): 2420. CrossRef
Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline
R.S. Guninski, F. Cuccia, F. Alongi, N. Andratschke, C. Belka, D. Bellut, M. Dahele, M. Josipovic, T.E. Kroese, P. Mancosu, G. Minniti, M. Niyazi, U Ricardi, P. Munck af Rosenschold, A. Sahgal, Y. Tsang, W.F.A.R. Verbakel, M. Guckenberger
Radiotherapy and Oncology.2024; 190: 109969. CrossRef
Metastatic Spinal Lesion with Minimal Epidural Compression: Surgical Treatment or Stereotactic Radiotherapy?
O. I. Kit, D. E. Zakondyrin, A. A. Grin, E. E. Rostorguev, Y. V. Przhedetskiy, P. G. Sakun, V. I. Voshedskii, B. V. Matevosian, T. S. Shepelya
Creative surgery and oncology.2024; 14(2): 127. CrossRef
Surgical Interventions Following Radiotherapy in Spinal Metastases with Intermediate Instability: A Risk Factor Analysis: The Korean Society of Spinal Tumor Multicenter Study (KSST 2022-02)
Se-Jun Park, Jin Ho Kim, Yong Chan Ahn, Woong Sub Koom, Hwa Kyung Byun, Young-Hoon Kim, Sang-Il Kim, Dong-Ho Kang
Cancers.2024; 16(14): 2554. CrossRef
Development of a novel 12-point grading system for evaluating epidural spinal cord compression and its clinical implications
Xuyong Cao, Weihao Jiang, Xiongwei Zhao, Haikuan Yu, Mingxing Lei, Yuncen Cao, Xiuyun Su, Yaosheng Liu
The Spine Journal.2023; 23(12): 1858. CrossRef
Efficacy of Total En Bloc Spondylectomy versus Stereotactic Ablative Radiotherapy for Single Spinal Metastasis
Dong-Ho Kang, Wooseok Lee, Bong-Soon Chang, Hyoungmin Kim, Sam Yeol Chang, Seong Hwa Hong, Jin Ho Kim, Hee Jung Son
Cancers.2023; 15(23): 5518. CrossRef
Radiomic modeling to predict risk of vertebral compression fracture after stereotactic body radiation therapy for spinal metastases
Chengcheng Gui, Xuguang Chen, Khadija Sheikh, Liza Mathews, Sheng-Fu L. Lo, Junghoon Lee, Majid A. Khan, Daniel M. Sciubba, Kristin J. Redmond
Journal of Neurosurgery: Spine.2022; 36(2): 294. CrossRef
Stereotactic body radiotherapy for spinal metastases: a review
Lanlan Guo, Lixin Ke, Ziyi Zeng, Chuanping Yuan, Ziwei Wu, Lei Chen, Lixia Lu
Medical Oncology.2022;[Epub] CrossRef
Treatment of Metastatic Spinal Disease; what the Radiologist needs to know
Stephen Supple, Shahjehan Ahmad, Santhosh Gaddikeri, Miral D. Jhaveri
The British Journal of Radiology.2022;[Epub] CrossRef
Spinal metastases 2021: a review of the current state of the art and future directions
Daniel M. Sciubba, Zach Pennington, Matthew W. Colman, C. Rory Goodwin, Ilya Laufer, Joshua C. Patt, Kristin J. Redmond, Philip Saylor, John H. Shin, Joseph H. Schwab, Andrew J. Schoenfeld
The Spine Journal.2021; 21(9): 1414. CrossRef
An updated algorithm for the treatment of spinal metastasis
Kawngwoo Park, Seong Son, Sang Gu Lee, En Kyung Cho, Hee Kyung Ahn, In Keun Park, Sun Jin Sym, Young Saing Kim
Neurofunction.2021; 17(2): 70. CrossRef
Separation surgery for metastatic epidural spinal cord compression: A qualitative review
Giuseppe Di Perna, Fabio Cofano, Cristina Mantovani, Serena Badellino, Nicola Marengo, Marco Ajello, Ludovico Maria Comite, Giuseppe Palmieri, Fulvio Tartara, Francesco Zenga, Umberto Ricardi, Diego Garbossa
Journal of Bone Oncology.2020; 25: 100320. CrossRef
Multidisciplinary management of metastatic spine disease: initial symptom-directed management
Jeremy M Steinberger, Frank Yuk, Amish H Doshi, Sheryl Green, Isabelle M Germano
Neuro-Oncology Practice.2020; 7(Supplement): i33. CrossRef

12,770 View
236 Download
17 Web of Science
16 Crossref

High-Dose Thoracic Re-irradiation of Lung Cancer Using Highly Conformal Radiotherapy Is Effective with Acceptable Toxicity: Ji Hyun Hong, Yeon-Sil Kim, Sea-Won Lee, So Jung Lee, Jin Hyung Kang, Suk Hee Hong, Ju-Young Hong, GeumSeong Cheon; Cancer Res Treat. 2019;51(3):1156-1166. Published online November 29, 2018; DOI: https://doi.org/10.4143/crt.2018.472

Abstract PDF PubReader ePub

Purpose
Thoracic re-irradiation (re-RT) of lung cancer has been challenged by the tolerance doses of normal tissues. We retrospectively analyzed local control, overall survival (OS) and toxicity after thoracic re-RT using highly conformal radiotherapy, such as intensity modulated radiotherapy and stereotactic body radiotherapy.
Materials and Methods
Thirty-one patients who received high-dose thoracic re-RT were analyzed. Doses were recalculated to determine biologically equivalent doses. The median interval to re-RT was 15.1 months (range, 4.4 to 56.3 months), the median initial dose was 79.2 Gy₁₀ (range, 51.75 to 150 Gy₁₀), and the median re-RT dose was 68.8 Gy₁₀ (range, 43.2 to 132 Gy₁₀).
Results
Eighteen (58.1%) and eleven (35.5%) patients showed loco-regional recurrence and distant metastasis, respectively, after 17.4 months of median follow-up. The 1-year and 2-year local control rates were 60.2% and 43.7%, respectively. The median loco-regional recurrence-free-survival (LRFS) was 15.4 months, and the median OS was 20.4 months. The cumulative and re-RT biologically equivalent dose for α/β=10 (BED₁₀) doses were the most significant prognostic factors. Cumulative BED₁₀≥145 Gy₁₀ and re-RT BED₁₀≥68.7 Gy₁₀ were significantly associated with longer OS (p=0.029 and p=0.012, respectively) and LRFS (p=0.003 and p=0.000, respectively). The most frequent acute toxicity was grade 1-2 pulmonary toxicity (41.9%). No acute grade 3 or higher toxicities occurred.
Conclusion
Our results show that high-dose thoracic re-RT of lung cancer can be safely delivered using highly conformal radiotherapy with favorable survival and acceptable toxicity. An optimal strategy to select patients who would benefit from re-RT is crucial in extending the indications and improving the efficacy with a sufficiently high dose.

Citations

Citations to this article as recorded by

High-Dose REirradiation for In-Field Recurrent Lung Cancer in the THOrax (RETHO): Outcomes of a Phase 2 Prospective Clinical Trial
Eugenio Cammareri, Marloes Duijm, Patrick V. Granton, Wilco Schillemans, Steven Petit, Jose Belderbos, Erik van Werkhoven, Robin Cornelissen, Joost L. Knegjens, Joost J. Nuyttens
International Journal of Radiation Oncology*Biology*Physics.2026; 124(5): 1329. CrossRef
Cumulative oesophageal dose and risk of high-grade toxicity in thoracic re-irradiation: a dose/toxicity analysis
Robert Rulach, Stephen Harrow, Anthony J. Chalmers, John Fenwick
Clinical and Translational Radiation Oncology.2026; 57: 101108. CrossRef
Cumulative lung dose–volume predictors of radiation pneumonitis in thoracic reirradiation: A systematic scoping review
Thomas Frédéric-Moreau, Nicolaus Andratschke, Delphine Antoni, Kevin Chua, Kim Cao, Georges Noel, Maxime Loo, Jonas Willmann, Ane Appelt, Arnaud Beddok
Critical Reviews in Oncology/Hematology.2026; 222: 105287. CrossRef
Stereotactic Lung Re-Irradiation After a First Course of Stereotactic Radiotherapy with In-Field Relapse: A Valuable Option to Be Considered
Assim Sahin, Edouard Romano, Alessio Casutt, Raphaël Moeckli, Véronique Vallet, Shaïma El Chammah, Mahmut Ozsahin, Rémy Kinj
Cancers.2025; 17(3): 366. CrossRef
American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary
Charles B. Simone, Arya Amini, Indrin J. Chetty, J. Isabelle Choi, Stephen G. Chun, Jessica Donington, Martin J. Edelman, Kristin A. Higgins, Larry L. Kestin, Pranshu Mohindra, Benjamin Movsas, George B. Rodrigues, Kenneth E. Rosenzweig, Igor I. Rybkin, A
International Journal of Radiation Oncology*Biology*Physics.2025; 123(1): 204. CrossRef
Re-irradiation of recurrent lung tumours: Associations between dose and 2-year survival
Robert Rulach, Stephen Harrow, Anthony J. Chalmers, John Fenwick
Clinical and Translational Radiation Oncology.2025; 55: 101036. CrossRef
Efficacy and safety of twice-daily accelerated hyperfractionated re-irradiation for thoracic malignancies
Victoria L. Doss, Cecilia F.P.M. de Sousa, Elaina Hales, Tinker Trent, Esi Hagan, Tsion Gebre, Anas Obaideen, Meti Negassa, Dezhi Liu, Chen Hu, Akila N. Viswanathan, Heng Li, K.Ranh Voong, Xun Jia, Todd McNutt, Rachel B. Ger, Russell K. Hales
Radiotherapy and Oncology.2025; 212: 111130. CrossRef
ACR-ARS Practice Parameter for the Performance of Proton Beam Therapy
Steven J. Frank, Indra J. Das, Charles B. Simone, Brian J. Davis, Curtiland Deville, Zhongxing Liao, Simon S. Lo, Susan L. McGovern, Rahul R. Parikh, Michael Reilly, William Small, Naomi R. Schechter
International Journal of Particle Therapy.2024; 13: 100021. CrossRef
Ultra-Hypofractionated Re-Irradiation with Anti-PD-1 Immunotherapy for Locoregionally Recurrent (after Radical Chemo-Radiotherapy) Non-Small Cell Lung Cancer
Konstantinos Filippatos, Ioannis M. Koukourakis, Stavros Anevlavis, Axiotis Giaktzidis, Michael I. Koukourakis
Cancers.2023; 15(20): 5083. CrossRef
Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review
Dorota Gabrys, Roland Kulik, Agnieszka Namysł-Kaletka
The British Journal of Radiology.2022;[Epub] CrossRef
High Dose Thoracic Re-Irradiation and Chemo-Immunotherapy for Centrally Recurrent NSCLC
Brane Grambozov, Markus Stana, Bernhard Kaiser, Josef Karner, Sabine Gerum, Elvis Ruznic, Barbara Zellinger, Raphaela Moosbrugger, Michael Studnicka, Gerd Fastner, Felix Sedlmayer, Franz Zehentmayr
Cancers.2022; 14(3): 573. CrossRef
Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
Life.2022; 12(2): 292. CrossRef
Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh
Radiation Oncology Journal.2021; 39(1): 24. CrossRef
Thoracic re-irradiation with 3D-conformal or more advanced techniques: A systematic review of treatment safety by the Re-irradiation Study Group of the Italian Association of Radiation and Oncology AIRO
Marta Maddalo, Elisa D’Angelo, Francesco Fiorica, Angela Argenone, Melissa Scricciolo, Salvatore Cozzi, Alessia Nardangeli, Francesco Dionisi, Gianluca Costantino, Stefano Vagge, Antonio Pontoriero, Vittorio Donato, Mariangela Massaccesi
Critical Reviews in Oncology/Hematology.2021; 167: 103500. CrossRef
Radiotherapy for head and neck tumours using an oral fixation and parameter acquisition device and TOMO technology: a randomised controlled study
Xiaofang Zhang, Tianlu Wang, Xinyan Xiao, Xia Li, Chen Yu Wang, Bo Huang, Lei He, Yingqiu Song
BMJ Open.2021; 11(11): e052542. CrossRef
The Medical Physics Management of Reirradiation Patients
Kelly C. Paradis, Martha M. Matuszak
Seminars in Radiation Oncology.2020; 30(3): 204. CrossRef
Reirradiation at local relapse of non-small cell lung cancer
D.V. Gogolin, I.A. Gulidov, Y.S. Mardynsky, T.Y. Antonenko, A.Y. Buksha
Onkologiya. Zhurnal imeni P.A.Gertsena.2020; 9(3): 48. CrossRef

11,458 View
269 Download
15 Web of Science
17 Crossref

Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418): Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2019;51(3):1041-1051. Published online November 1, 2018; DOI: https://doi.org/10.4143/crt.2018.424

Abstract PDF PubReader ePub

Purpose
We compared the oncologic outcomes of breast-conserving surgery plus radiation therapy (BCS+RT) and modified radical mastectomy (MRM) under anthracycline plus taxane-based (AT) regimens and investigated the role of adjuvant radiation therapy (RT) in patients with pathologic N1 (pN1) breast cancer treated by mastectomy.
Materials and Methods
We retrospectively reviewed the medical records of 2,011 patients with pN1 breast cancer who underwent BCS+RT or MRM alone at 12 institutions between January 2006 and December 2010. Two-to-one propensity score matching was performed for balances in variables between the groups.
Results
The median follow-up duration for the total cohort was 69 months (range, 1 to 114 months). After propensity score matching, 1,074 patients (676 in the BCS+RT group and 398 in the MRM-alone group) were analyzed finally. The overall survival, disease-free survival, locoregional failure-free survival, and regional failure-free survival (RFFS) curves of the BCS+RT group vs. MRM-alone group were not significantly different. The subgroup analysis revealed that in the group with both lymphovascular invasion (LVI) and histologic grade (HG) III, the BCS+RT showed significantly superior RFFS (p=0.008). Lymphedema (p=0.007) and radiation pneumonitis (p=0.031) occurred more frequently in the BCS+RT group than in the MRM-alone group, significantly.
Conclusion
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer. However, BCS+RT group showed superior RFFS to MRM-alone group in the patients with LVI and HG III. Adjuvant RT might be considerable for pN1 breast cancer patients with LVI and HG III.

Citations

Citations to this article as recorded by

Investigation of the clinical benefits of regular breath-holding training utilizing surface guided radiation therapy technology for patients with left breast cancer
Hongming Li, Zheng Miao, Jie Shen, Jianing Xiao, Zhiwei Yang, Wei Tian, Xiansong Sun, Zhen Zhou, Jing Shen, Jie Qiu
Journal of Radiation Research and Applied Sciences.2025; 18(2): 101393. CrossRef
21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery
Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang
The Breast.2024; 74: 103679. CrossRef
Assessing Radiation Effects on Chemo-Treated BT20 and 4T1 Breast Cancer, and Neuroblastoma Cell Lines: A Study of Single and Multiple-Cell Ionization via Infrared Laser Trapping
Mulugeta S. Goangul, Daniel B. Erenso, Ying Gao, Li Chen, Kwame O. Eshun, Gisela Alvarez, Horace T. Crogman
Radiation.2024; 4(1): 85. CrossRef
Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis
Kiran K Rajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter
BJS Open.2024;[Epub] CrossRef
Radiotherapy dosimetry and radiotherapy related complications of immediate implant-based reconstruction after breast cancer surgery
Yu Zhang, Fuxiu Ye, Yun Teng, Jin Zheng, Chunlu Li, Ruilan Ma, Haichen Zhang
Frontiers in Oncology.2023;[Epub] CrossRef
Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients
Gabriel De la Cruz Ku, Manish Karamchandani, Diego Chambergo-Michilot, Alexis R. Narvaez-Rojas, Michael Jonczyk, Fortunato S. Príncipe-Meneses, David Posawatz, Salvatore Nardello, Abhishek Chatterjee
Annals of Surgical Oncology.2022; 29(10): 6163. CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
BMC Cancer.2022;[Epub] CrossRef
Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions
Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Chemo-treated 4T1 breast cancer cells radiation response measured by single and multiple cell ionization using infrared laser trap
Endris Muhammed, Li Chen, Ying Gao, Daniel Erenso
Scientific Reports.2019;[Epub] CrossRef

11,974 View
323 Download
11 Web of Science
9 Crossref

Comparative Effectiveness of Abdominal versus Laparoscopic Radical Hysterectomy for Cervical Cancer in the Postdissemination Era: Jin Hee Kim, Kyungjoo Kim, Seo Jin Park, Jung-Yun Lee, Kidong Kim, Myong Cheol Lim, Jae Weon Kim; Cancer Res Treat. 2019;51(2):788-796. Published online September 11, 2018; DOI: https://doi.org/10.4143/crt.2018.120

Abstract PDF Supplementary Material PubReader ePub

Purpose
Despite the benefits of minimally invasive surgery for cervical cancer, there are a lack of randomized trials comparing laparoscopic radical hysterectomy and abdominal radical hysterectomy. We compared morbidity, cost of care, and survival between abdominal radical hysterectomy and laparoscopic radical hysterectomy for cervical cancer.
Materials and Methods
We used the Korean nationwide database to identify women with cervical cancer who underwent radical hysterectomy from January 1, 2011 to December 31, 2014. Patients who underwent abdominal radical hysterectomy were compared to those who underwent laparoscopic radical hysterectomy. Perioperative morbidity, the use of adjuvant therapy, and survival were evaluated after propensity score balancing.
Results
We identified 6,335 patients, including 3,235 who underwent abdominal radical hysterectomy and 3,100 who underwent laparoscopic radical hysterectomy. The use of laparoscopic radical hysterectomy increased from 46.1% in 2011 to 51.8% in 2014. Patients who were younger, had a more recent year of diagnosis, and were treated in the metropolitan area were more likely to undergo a laparoscopic procedure (p < 0.001). Compared to abdominal radical hysterectomy, laparoscopic radical hysterectomy was associated with lower rates of complication, fewertransfusions, a shorter hospital stay, less adjuvant therapy, and reduced total medical costs (p < 0.001). Laparoscopic surgery was associated with a better overall survival than abdominal operation (hazard ratio, 0.74; 95% confidence interval, 0.64 to 0.85).
Conclusion
In the postdissemination era, laparoscopic radical hysterectomy was associated with more favorable morbidity profiles, a lower cost of care, and comparable survival than abdominal radical hysterectomy.

Citations

Citations to this article as recorded by

Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial
Se Ik Kim, Jae-Weon Kim, Janice S. Kwon, Sarah E. Ferguson, Alexandra Sebastianelli, Paul Bessette, Sven Mahner, Tristan Gauthier, Cor de Kroon, Willemien van Driel, Karin Williamson, Frederic Goffin, Stephan Polterauer, Brynhildur Eyjólfsdóttir, Jung-Yun
Gynecologic Oncology.2026; 205: 37. CrossRef
Patient-centered valuation of minimally invasive surgery in cervical cancer: a discrete choice experiment
Jeongyun Kim, Jieun Jang, Sokbom Kang
Journal of Gynecologic Oncology.2026;[Epub] CrossRef
Laparoscopic type 3 radical hysterectomy with enclosed colpotomy using the Bakay technique for early-stage cervical cancer: a retrospective case series
Gamze Savci, Eda Adeviye Sahin, Hanifi Sahin, Mehmet Faruk Olcenoglu, Kadir Bakay, Turan Sahin
BMC Women's Health.2026;[Epub] CrossRef
Effects of spinal versus general anesthesia on serum oxidative stress markers and cytokine release after abdominal hysterectomy: a non-randomized trial
Morteza Hashemian, Shahrzad Sahebdad-Khabisi, Zahra Honarvar, Zohreh Torabinejad, Hosein Taravati, Fatemeh Doost Mohammadi, Ladan Amirkhosravi
Scientific Reports.2025;[Epub] CrossRef
Internal Validation of Predictive Models for Recurrence-Free Survival and Risk of Recurrence in Patients with Figo Stages I–IV Cervical Cancer
Jorge Cea García, Francisco Márquez Maraver, M. Carmen Rubio Rodríguez, Laura Ríos-Pena, Inmaculada Rodríguez Jiménez
Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Lymph Node Yield, Positivity Ratio, and Overall Survival in Laparoscopic Versus Open Radical Hysterectomy for Carcinoma Cervix: A Retrospective Analysis
Subbiah Shanmugam, Jagadish Singh, Mohanasundaram Natarajan
Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Research Progress on the Therapeutic Effect of Laparoscopic Surgery without Uterine Ma-nipulator on Cervical Cancer
潇予刘
Advances in Clinical Medicine.2023; 13(08): 13249. CrossRef
Meta-analysis of laparoscopic radical hysterectomy, excluding robotic assisted versus open radical hysterectomy for early stage cervical cancer
Greg Marchand, Ahmed Taher Masoud, Ahmed Abdelsattar, Alexa King, Hollie Ulibarri, Julia Parise, Amanda Arroyo, Catherine Coriell, Sydnee Goetz, Carmen Moir, Atley Moberly, Malini Govindan
Scientific Reports.2023;[Epub] CrossRef
Comparison between laparoscopic and abdominal radical hysterectomy for cervical adenosquamous carcinoma at stage IA2 to IIA2: A multicenter retrospective study
Xiaohui Teng, Shan Kang, Weili Li, Hongmei Ding, Bin Ling, Lin Zhu, Danbo Wang, Jinghe Lang, Ping Liu, Chunlin Chen
Journal of Obstetrics and Gynaecology Research.2023; 49(6): 1592. CrossRef
The sealing effect of magnetic-sealing uterine manipulator in isolated uterus from patients with early-stage cervical cancer: a pre-clinical study
Xue Zhou, Dongxin Liang, Qing Li, Lanbo Zhao, Yadi Bin, Feng Ma, Rongqian Wu, Yi Lv, Qiling Li
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
External Validation of the eCura System for Undifferentiated-Type Early Gastric Cancer with Noncurative Endoscopic Resection
Hyo-Joon Yang, Young-Il Kim, Ji Yong Ahn, Kee Don Choi, Sang Gyun Kim, Seong Woo Jeon, Jie-Hyun Kim, Sung Kwan Shin, Hyuk Lee, Wan Sik Lee, Gwang Ha Kim, Jae Myung Park, Woon Geon Shin, Il Ju Choi
Gut and Liver.2023; 17(4): 537. CrossRef
Internal Validation of a Predictive Model for Overall Survival in Patients with FIGO stages I–IV Cervical Cancer
Jorge Cea García, Francisco Márquez Maraver, Inmaculada Rodríguez Jiménez, Laura Ríos-Pena, M. Carmen Rubio Rodríguez
Indian Journal of Gynecologic Oncology.2023;[Epub] CrossRef
A meta-analysis of survival after minimally invasive radical hysterectomy versus abdominal radical hysterectomy in cervical cancer: center-associated factors matter
Si Sun, Jing Cai, Ruixie Li, Yujia Wang, Jing Zhao, Yuhui Huang, Linjuan Xu, Qiang Yang, Zehua Wang
Archives of Gynecology and Obstetrics.2022; 306(3): 623. CrossRef
Association of preoperative cone biopsy with recurrences after radical hysterectomy
Rüdiger Klapdor, Hermann Hertel, Laura Delebinski, Peter Hillemanns
Archives of Gynecology and Obstetrics.2022; 305(1): 215. CrossRef
Comparison between laparoscopic and abdominal radical hysterectomy for low-risk cervical cancer: a multicentre retrospective study
Zhiqiang Li, Chunlin Chen, Ping Liu, Anwei Lu, Hongwei Zhao, Xuemei Zhan, Hui Duan, Pengfei Li, Weidong Zhao, Jilong Yao, Donglin Li, Haixia Jiang, Mubiao Liu, Xiaonong Bin, Jinghe Lang
Archives of Gynecology and Obstetrics.2022; 305(2): 449. CrossRef
Perioperative morbidity of different operative approaches in early cervical carcinoma: a systematic review and meta-analysis comparing minimally invasive versus open radical hysterectomy
J. Kampers, E. Gerhardt, P. Sibbertsen, T. Flock, H. Hertel, R. Klapdor, M. Jentschke, P. Hillemanns
Archives of Gynecology and Obstetrics.2022; 306(2): 295. CrossRef
Retrospective Analysis of Cervical Cancer Treatment Outcomes: Ten Years of Experience with the Vaginal Assisted Radical Laparoscopic Hysterectomy VARLH
R. Wojdat, E. Malanowska, Harald Krentel
BioMed Research International.2022;[Epub] CrossRef
Comparison of Minimally Invasive Versus Abdominal Radical Hysterectomy for Early-Stage Cervical Cancer: An Updated Meta-Analysis
Mengting Zhang, Wei Dai, Yuexiu Si, Yetan Shi, Xiangyuan Li, Ke Jiang, Jingyi Shen, Liying Ying
Frontiers in Oncology.2022;[Epub] CrossRef
The Impaction of Laparoscopic versus Laparotomy for Lymphovascular Space Invasion of Early Cervical Cancer
Wei Huang, Yina Wang, Fanchun Yang, Ning Luo, Guihai Ai, Yuliang Wu, Zhongping Cheng
Gynecology and Minimally Invasive Therapy.2022; 11(1): 17. CrossRef
Retrospective Comparison of Laparoscopic versus Open Radical Hysterectomy for Early-Stage Cervical Cancer in a Single Tertiary Care Institution from Lithuania between 2009 and 2019
Danuta Vasilevska, Dominika Vasilevska, Andrzej Semczuk, Vilius Rudaitis
Medicina.2022; 58(4): 553. CrossRef
The incidence of postoperative symptomatic lymphocele after pelvic lymphadenectomy between abdominal and laparoscopic approach: a systemic review and meta-analysis
Jong Ha Hwang, Bo Wook Kim
Surgical Endoscopy.2022; 36(10): 7114. CrossRef
Comparison of Survival Outcomes between Minimally Invasive Surgery and Open Radical Hysterectomy in Early-Stage Cervical Cancer
I.-Ning Chen, I.-Te Wang, Hsueh-Yu Mu, J.-Timothy Qiu, Wei-Min Liu, Ching-Wen Chang, Yen-Hsieh Chiu
Cancers.2022; 14(9): 2117. CrossRef
Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study
Sabrina Piedimonte, Gregory R. Pond, Marie Plante, Gregg Nelson, Janice Kwon, Alon Altman, Tomer Feigenberg, Laurie Elit, Susie Lau, Jeanelle Sabourin, Karla Willows, Christa Aubrey, Ji-Hyun Jang, Ly-Ann Teo-Fortin, Norah Cockburn, Nora-Beth Saunders, Sar
Gynecologic Oncology.2022; 166(2): 230. CrossRef
The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes
Mario M. Leitao, Qin C. Zhou, Benny Brandt, Alexia Iasonos, Vasileios Sioulas, Katherine Lavigne Mager, Mark Shahin, Shaina Bruce, Destin R. Black, Carrie G. Kay, Meeli Gandhi, Maira Qayyum, Jennifer Scalici, Nathaniel L. Jones, Rajesh Paladugu, Jubilee B
Gynecologic Oncology.2022; 166(3): 417. CrossRef
New Insights in the Diagnosis of Rare Adenocarcinoma Variants of the Cervix—Case Report and Review of Literature
Cristina Secosan, Oana Balint, Aurora Ilian, Lavinia Balan, Ligia Balulescu, Andrei Motoc, Delia Zahoi, Dorin Grigoras, Laurentiu Pirtea
Healthcare.2022; 10(8): 1410. CrossRef
Learning curve could affect oncologic outcome of minimally invasive radical hysterectomy for cervical cancer
Seongmin Kim, Kyung Jin Min, Sanghoon Lee, Jin Hwa Hong, Jae Yun Song, Jae Kwan Lee, Nak Woo Lee
Asian Journal of Surgery.2021; 44(1): 174. CrossRef
Risk factors of lymph node metastasis after non-curative endoscopic resection of undifferentiated-type early gastric cancer
Hyo-Joon Yang, Jae-Young Jang, Sang Gyun Kim, Ji Yong Ahn, Su Youn Nam, Jie-Hyun Kim, Byung-Hoon Min, Wan-Sik Lee, Bong Eun Lee, Moon Kyung Joo, Jae Myung Park, Woon Geon Shin, Hang Lak Lee, Tae-Geun Gweon, Moo In Park, Jeongmin Choi, Chung Hyun Tae, Youn
Gastric Cancer.2021; 24(1): 168. CrossRef
Clinical outcomes of endoscopic resection for undifferentiated intramucosal early gastric cancer larger than 2 cm
Hyo-Joon Yang, Su Youn Nam, Byung-Hoon Min, Ji Yong Ahn, Jae-Young Jang, Jung Kim, Jie-Hyun Kim, Wan-Sik Lee, Bong Eun Lee, Moon Kyung Joo, Jae Myung Park, Woon Geon Shin, Hang Lak Lee, Tae-Geun Gweon, Moo In Park, Jeongmin Choi, Chung Hyun Tae, Young-Il
Gastric Cancer.2021; 24(2): 435. CrossRef
Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study
Dong Wook Shin, Jaeman Bae, Johyun Ha, Kyu-Won Jung
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery
S. Allison Staley, Katherine R. Tucker, Paola A. Gehrig, Leslie H. Clark
Gynecologic Oncology.2021; 160(2): 384. CrossRef
Comparison of survival outcomes between laparoscopic and abdominal radical hysterectomy for early-stage cervical cancer: A French multicentric study
François Zaccarini, Anna Santy, Yohann Dabi, Vincent Lavoue, Xavier Carcopino, Sofiane Bendifallah, Amélie Benbara, Pierre Collinet, Geoffroy Canlorbe, Emilie Raimond, Olivier Graesslin, Lobna Ouldamer, Emile Daraï, Cyrille Huchon, François Golfier, Cyril
Journal of Gynecology Obstetrics and Human Reproduction.2021; 50(2): 102046. CrossRef
Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis
Juliana Rodriguez, Jose Alejandro Rauh-Hain, James Saenz, David Ortiz Isla, Gabriel Jaime Rendon Pereira, Diego Odetto, Fabio Martinelli, Vladimir Villoslada, Ignacio Zapardiel, Lina Maria Trujillo, Milagros Perez, Marcela Hernandez, Jose Martin Saadi, Fr
International Journal of Gynecological Cancer.2021; 31(4): 504. CrossRef
Minimally Invasive Radical Hysterectomy for Cervical Cancer: A Systematic Review and Meta-analysis
Anna Jo Bodurtha Smith, Tiffany Nicole Jones, Diana Miao, Amanda Nickles Fader
Journal of Minimally Invasive Gynecology.2021; 28(3): 544. CrossRef
Comparison of oncological outcomes and major complications between laparoscopic radical hysterectomy and abdominal radical hysterectomy for stage IB1 cervical cancer with a tumour size less than 2 cm
Zhiqiang Li, Chunlin Chen, Ping Liu, Hui Duan, Mubiao Liu, Yan Xu, Pengfei Li, Wenling Zhang, Haixia Jiang, Xiaonong Bin, Jinghe Lang
European Journal of Surgical Oncology.2021; 47(8): 2125. CrossRef
Cervical Cancer Surgery
Fan Chun Yang, Wei Huang, Weihong Yang, Jie Liu, Guihai Ai, Ning Luo, Jing Guo, Peng Teng Chua, Zhongping Cheng
Gynecology and Minimally Invasive Therapy.2021; 10(2): 75. CrossRef
Protective operative techniques in radical hysterectomy in early cervical carcinoma and their influence on disease-free and overall survival: a systematic review and meta-analysis of risk groups
Johanna Kampers, E. Gerhardt, P. Sibbertsen, T. Flock, R. Klapdor, H. Hertel, M. Jentschke, P. Hillemanns
Archives of Gynecology and Obstetrics.2021; 304(3): 577. CrossRef
The incidence of urologic complications requiring urologic procedure in radical hysterectomy and difference between abdominal radical hysterectomy and laparoscopic radical hysterectomy
Hyeongsu Kim, Ho Jin Jeong, Bo Wook Kim, Jong Ha Hwang
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Long-term Outcomes of Undifferentiated-Type Early Gastric Cancer with Positive Horizontal Margins after Endoscopic Resection
Hyo-Joon Yang, Wan-Sik Lee, Bong Eun Lee, Ji Yong Ahn, Jae-Young Jang, Joo Hyun Lim, Su Youn Nam, Jie-Hyun Kim, Byung-Hoon Min, Moon Kyung Joo, Jae Myung Park, Woon Geon Shin, Hang Lak Lee, Tae-Geun Gweon, Moo In Park, Jeongmin Choi, Chung Hyun Tae, Young
Gut and Liver.2021; 15(5): 723. CrossRef
Laparoscopic radical hysterectomy has higher risk of perioperative urologic complication than abdominal radical hysterectomy: a meta-analysis of 38 studies
Jong Ha Hwang, Bo Wook Kim
Surgical Endoscopy.2020; 34(4): 1509. CrossRef
Effect of laparoscopic versus abdominal radical hysterectomy on major surgical complications in women with stage IA-IIB cervical cancer in China, 2004–2015
Cong Liang, Ping Liu, Zhumei Cui, Zhiqing Liang, Xiaonong Bin, Jinghe Lang, Chunlin Chen
Gynecologic Oncology.2020; 156(1): 115. CrossRef
Surgical Management of Early Cervical Cancer: When Is Laparoscopic Appropriate?
Stefano Greggi, Gennaro Casella, Felice Scala, Francesca Falcone, Serena Visconti, Cono Scaffa
Current Oncology Reports.2020;[Epub] CrossRef
Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes
Benny Brandt, Vasileios Sioulas, Derman Basaran, Theresa Kuhn, Katherine LaVigne, Ginger J. Gardner, Yukio Sonoda, Dennis S. Chi, Kara C. Long Roche, Jennifer J. Mueller, Elizabeth L. Jewell, Vance A. Broach, Oliver Zivanovic, Nadeem R. Abu-Rustum, Mario
Gynecologic Oncology.2020; 156(3): 591. CrossRef
Changing treatment landscape for early cervical cancer: outcomes reported with minimally invasive surgery compared with an open approach
Alexander Melamed, Pedro T. Ramirez
Current Opinion in Obstetrics & Gynecology.2020; 32(1): 22. CrossRef
Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer
Roni Nitecki, Pedro T. Ramirez, Michael Frumovitz, Kate J. Krause, Ana I. Tergas, Jason D. Wright, J. Alejandro Rauh-Hain, Alexander Melamed
JAMA Oncology.2020; 6(7): 1019. CrossRef
Comparison of laparoscopic versus open radical hysterectomy in patients with early-stage cervical cancer: a multicenter study in China
Ting wen yi Hu, Yue Huang, Na Li, Dan Nie, Zhengyu Li
International Journal of Gynecological Cancer.2020; 30(8): 1143. CrossRef
Laparoscopic versus open radical hysterectomy in women with early stage cervical cancer: A systematic review and meta-analysis
Tanitra Tantitamit, Kuan-Gen Huang, Chyi-Long Lee
Taiwanese Journal of Obstetrics and Gynecology.2020; 59(4): 481. CrossRef
Primary conization overcomes the risk of developing local recurrence following laparoscopic radical hysterectomy in early stage cervical cancer
Giorgio Bogani, Antonino Ditto, Valentina Chiappa, Ciro Pinelli, Cristina Sonetto, Francesco Raspagliesi
International Journal of Gynecology & Obstetrics.2020; 151(1): 43. CrossRef
Survival After Minimally Invasive vs. Open Radical Hysterectomy for Cervical Cancer: A Meta-Analysis
Yizi Wang, Bo Li, Fang Ren, Zixuan Song, Ling Ouyang, Kuiran Liu
Frontiers in Oncology.2020;[Epub] CrossRef
Laparoscopic regional radical hysterectomy showed promising clinical outcomes in early-stage cervical cancer
Weihong Yang, Rong Chen, Caixia Li, Li Li, Ning Luo, Zhongping Cheng
Gynecology and Minimally Invasive Therapy.2020; 9(4): 220. CrossRef
A Retrospective Comparison of the Outcomes of Laparoscopic and Open Radical Hysterectomy for Early and Advanced Cancer of the Cervix, in the Post-LACC Era
Subbiah Shanmugam, Sujay Susikar, Syed Afroze Hussain, T. Bharanidharan, Rajiv Michael
Indian Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1–IIA2 cervical cancer
Se Ik Kim, Jae Hyun Cho, Aeran Seol, Young Im Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
Gynecologic Oncology.2019; 153(1): 3. CrossRef
Minimally-Invasive Radical Hysterectomy for Cancer of the Cervix: The Perspective of the Society of Gynecologic Oncology of Canada (GOC)
James R. Bentley
Journal of Obstetrics and Gynaecology Canada.2019; 41(2): 143. CrossRef
Hystérectomie radicale à effraction minimale pour le traitement d'un cancer du col de l'utérus : point de vue de la GOC
James R. Bentley
Journal of Obstetrics and Gynaecology Canada.2019; 41(2): 146. CrossRef
Laparoscopic radical hysterectomy with transvaginal closure of vaginal cuff – a multicenter analysis
Christhardt Köhler, Hermann Hertel, Jörg Herrmann, Simone Marnitz, Peter Mallmann, Giovanni Favero, Andrea Plaikner, Peter Martus, Mieczyslaw Gajda, Achim Schneider
International Journal of Gynecological Cancer.2019; 29(5): 845. CrossRef
After the Laparoscopic Approach to Cervical Cancer (LACC) trial: Korean Society of Gynecologic Oncology (KSGO) survey
Miseon Kim, Yong Beom Kim, Jae-Weon Kim
Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea
Se Ik Kim, Maria Lee, Sungyoung Lee, Dong Hoon Suh, Hee Seung Kim, Kidong Kim, Hyun Hoon Chung, Jae Hong No, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Yong Beom Kim
Gynecologic Oncology.2019; 155(1): 75. CrossRef

15,420 View
500 Download
56 Web of Science
56 Crossref

Long-term Outcomes of One Stage Surgery Using Transanal Colorectal Tube for Acute Colorectal Obstruction of Stage II/III Distal Colon Cancer: Yusuke Okuda, Tomonori Yamada, Yoshikazu Hirata, Takaya Shimura, Ryuzo Yamaguchi, Eiji Sakamoto, Satoshi Sobue, Takahiro Nakazawa, Hiromi Kataoka, Takashi Joh; Cancer Res Treat. 2019;51(2):474-482. Published online June 6, 2018; DOI: https://doi.org/10.4143/crt.2018.059

Abstract PDF PubReader ePub

Purpose
Since oncological outcomes of transanal colorectal tube (TCT) placement, an endoscopic treatment for colorectal cancer (CRC) with acute colorectal obstruction (ACO), remain unknown, this study analyzed long-term outcomes of TCT placement for stage II/III CRC with ACO.
Materials and Methods
Data were retrospectively reviewed from consecutive patients with distal stage II/III CRC who underwent surgery between January 2007 and December 2011 at two Japanese hospitals. One hospital conducted emergency surgery and the other performed TCT placement as the standard treatment for all CRCs with ACO. Propensity score (PS) matching was used to adjust baseline characteristics between two groups.
Results
Among 754 patients with distal stage II/III CRC, 680 did not have ACO (non-ACO group) and 74 had ACO (ACO group). The PS matching between both hospitals identified 234 pairs in the non-ACO group and 23 pairs in the ACO group. In the non-ACO group, the surgical quality was equivalent between the two institutions, with no significant differences in overall survival (OS) and disease-free survival (DFS). In the ACO group, the rate of primary resection/anastomosis was higher in the TCT group than in the surgery group (87.0% vs. 26.1%, p < 0.001). No significant differences were noted between the surgery and the TCT groups in OS (5-year OS, 61.9% vs. 51.5%; p=0.490) and DFS (5-year DFS, 45.9% vs. 38.3%; p=0.658).
Conclusion
TCT placement can achieve similar long-term outcomes to emergency surgery, with a high rate of primary resection/anastomosis for distal stage II/III colon cancer with ACO.

Citations

Citations to this article as recorded by

Effectiveness of self-abdominal massage on gastrointestinal function in postoperative ileus: a randomised controlled trial protocol
Yaokai Ma, Huan Wang, Shoufang Liu, Zhixian Xu, Yinlong Cao, Guimao Wang, Xuan Liu, Kaiyue Zhang, Guangxin Guo
BMJ Open.2026; 16(2): e109026. CrossRef
Short-term outcomes of self-expanding metallic stents and transanal colorectal tubes as a bridge to surgery for obstructive colon cancer: a nationwide retrospective study
Hiroaki Tsuji, Takashi Shigeno, Marie Hanaoka, Yasuko Aoyagi, Yudai Yamamoto, Shinichi Yamauchi, Hiroyasu Kagawa, Masanori Tokunaga, Kiyohide Fushimi, Yusuke Kinugasa
Surgery Today.2026;[Epub] CrossRef
Which treatment strategy is optimal for acute left-sided malignant colonic obstruction? A Bayesian meta-analysis
Kaibo Ouyang, Zifeng Yang, Yuesheng Yang, Junjiang Wang, Deqing Wu, Yong Li
International Journal of Colorectal Disease.2023;[Epub] CrossRef
A multicenter case–control study of self-expanding metallic stent versus trans-anal colorectal tube for stage II/III non-right-sided obstructive colon cancer
Yusuke Okuda, Takaya Shimura, Konomu Uno, Tomonori Yamada, Takayuki Nukui, Takashi Mizushima, Yuya Takenaka, Keisuke Itoh, Yuki Inagaki, Takanori Ozeki, Kazuhiro Nagao, Masahide Ebi, Erika Uchida, Satoshi Nomura, Yu Nojiri, Shozo Togawa, Naomi Sugimura, S
Journal of Gastroenterology.2023; 58(3): 217. CrossRef
Long-term and short-term outcomes of laparoscopic versus open resection following tube decompression for obstructive colorectal cancer: a single-center retrospective study
Kiyoaki Sugiura, Yuki Seo, Hikaru Aoki, Yoshihiko Onishi, Yusuke Nishi, Norihiro Kishida, Motomu Tanaka, Yasuhiro Ito, Hideyuki Tokura, Takayuki Takahashi
Surgery Today.2022; 52(9): 1284. CrossRef
Comparison of the prognosis of four different treatment strategies for acute left malignant colonic obstruction: a systematic review and network meta-analysis
Ling Tan, Zi-lin Liu, Meng-ni Ran, Ling-han Tang, Yan-jun Pu, Yi-lei Liu, Zhou Ma, Zhou He, Jiang-wei Xiao
World Journal of Emergency Surgery.2021;[Epub] CrossRef
A nomogram model for predicting prognosis of obstructive colorectal cancer
Jian Lv, Yuan yuan Liu, Yi tao Jia, Jing li He, Guang yao Dai, Peng Guo, Zhao long Zhao, Yan ni Zhang, Zhong xin Li
World Journal of Surgical Oncology.2021;[Epub] CrossRef
The long non‐coding RNA HCG18 promotes the growth and invasion of colorectal cancer cells through sponging miR‐1271 and upregulating MTDH/Wnt/β‐catenin
Shunle Li, Tao Wu, Di Zhang, Xiaoli Sun, Xinwu Zhang
Clinical and Experimental Pharmacology and Physiology.2020; 47(4): 703. CrossRef
MicroRNA‐876‐5p represses the cell proliferation and invasion of colorectal cancer through suppressing YAP signalling via targeting RASAL2
Li Ren, Zhiyong Zhang, Yun Feng, Miaosha Luo, Zhiming Hao
Clinical and Experimental Pharmacology and Physiology.2020; 47(5): 867. CrossRef
Pathological impact of transanal colorectal tube for obstructive colorectal cancer
Yusuke Okuda, Takaya Shimura, Hiroyuki Kato, Tomonori Yamada, Yoshikazu Hirata, Makoto Natsume, Hiroyasu Iwasaki, Ryuzo Yamaguchi, Eiji Sakamoto, Satoru Takahashi, Hiromi Kataoka
Surgical Endoscopy.2020; 34(9): 4011. CrossRef

10,232 View
241 Download
11 Web of Science
10 Crossref

Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases: Sebastian Stintzing, Jobst von Einem, Christoph Fueweger, Alfred Haidenberger, Michael Fedorov, Alexander Muavcevic; Cancer Res Treat. 2019;51(1):187-193. Published online April 16, 2018; DOI: https://doi.org/10.4143/crt.2017.594

Abstract PDF PubReader ePub

Purpose
The treatment of liver metastases with local procedures is a fast progressing field. For the most, long-term survival data is missing raising questions with regard to the efficacy of such modalities when compared to surgical resection. Radiosurgery using the CyberKnife device enables the treatment of liver lesions with a single-session approach. Here we present long-term survival data to explore the curative potential of this strategy.
Materials and Methods
Patients with oligo-metastatic disease limited to the liver have been treated with single-session or hypo-fractioned radiosurgery in curative intent and prospectively followed until death. Follow-up (FU) was performed using magnetic resonance imaging (MRI) 2 months after radiation and at 3-month intervals for the first 2 years. After that annual computed tomography or MRI scans were performed until 5 years post-treatment. Local recurrence in the radiated volume and recurrence outside the treated volume were used to define local and distant progression. Survival times were censored at the time of the last FU.
Results
One hundred twenty-six patients treated between 2005 and 2015 with 194 lesions were included into this study. Median FU was 30.0 months. According to Response Evaluation Criteria in Solid Tumors, 55.2% had a complete remission and 11.3% a partial remission. Seventy-two point two percent recurred outside the radiated lesion and median overall survival was 35.2 months with a 3-year survival rate of 47.7%.
Conclusion
This is currently the largest cohort of stereotactic body radiation therapy treated liver lesions with a median long-term follow of 30 months. Robotic radiosurgery using a single session approach has a high efficacy to control the radiated lesion with the potential to cure patients.

Citations

Citations to this article as recorded by

Stereotactic Body Radiation therapy for Liver Metastases: Systematic Review and Meta-Analysis With International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines
Ciro Franzese, Alexander V. Louie, Rupesh Kotecha, Zhenwei Zhang, Matthias Guckenberger, Mi-Sook Kim, Alison C. Tree, Ben J. Slotman, Arjun Sahgal, Marta Scorsetti
Practical Radiation Oncology.2025; 15(2): e172. CrossRef
Prospective planning comparison of magnetic resonance-guided vs. internal target volume-based stereotactic body radiotherapy of hepatic metastases – Which patients do really benefit from an MR-linac?
Philipp Hoegen-Saßmannshausen, C. Katharina Renkamp, Hoi Hin Lau, David Neugebauer, Nina Niebuhr, Carolin Buchele, Fabian Schlüter, Elisabetta Sandrini, Line Hoeltgen, Fabian Weykamp, Sebastian Regnery, Jakob Liermann, Eva Meixner, Kevin Zhang, Oliver Sed
Clinical and Translational Radiation Oncology.2025; 52: 100941. CrossRef
Robotic Stereotactic Body Radiation Therapy for Oligometastatic Liver Metastases: A Systematic Review of the Literature and Evidence Quality Assessment
Ilektra Kyrochristou, Ilias Giannakodimos, Maria Tolia, Ioannis Georgakopoulos, Nikolaos Pararas, Francesk Mulita, Nikolaos Machairas, Dimitrios Schizas
Diagnostics.2024; 14(10): 1055. CrossRef
Effectiveness of Robotic Stereotactic Radiotherapy in Patients Undergoing Re-irradiation: A Review
Ahamed Badusha Mohamed Yoosuf, Salem Alshehri, Mohd Zahri Abdul Aziz, Syahir Mansor, Gokula Kumar Appalanaido, Mamdouh Alqathami
Cureus.2023;[Epub] CrossRef
Stereotactic body radiation therapy in patients with liver oligometastases from colorectal cancer: a systematic review
A. N. Moskalenko, V. K. Lyadov, I. V. Sagaydak, M. V. Chernykh, N. N. Britskaya
Surgery and Oncology.2022; 12(1): 49. CrossRef
Anti-EGFR Therapy Induces EGF Secretion by Cancer-Associated Fibroblasts to Confer Colorectal Cancer Chemoresistance
Colleen M. Garvey, Roy Lau, Alyssa Sanchez, Ren X. Sun, Emma J. Fong, Michael E. Doche, Oscar Chen, Anthony Jusuf, Heinz-Josef Lenz, Brent Larson, Shannon M. Mumenthaler
Cancers.2020; 12(6): 1393. CrossRef

10,551 View
157 Download
6 Web of Science
6 Crossref

First
Prev
Page of 3
Next
Last

Search